NZ724464B2 - Jak1 inhibitors for the treatment of myelodysplastic syndromes - Google Patents
Jak1 inhibitors for the treatment of myelodysplastic syndromes Download PDFInfo
- Publication number
- NZ724464B2 NZ724464B2 NZ724464A NZ72446415A NZ724464B2 NZ 724464 B2 NZ724464 B2 NZ 724464B2 NZ 724464 A NZ724464 A NZ 724464A NZ 72446415 A NZ72446415 A NZ 72446415A NZ 724464 B2 NZ724464 B2 NZ 724464B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pyrrolo
- pyrimidinyl
- methyl
- trifluoromethyl
- acetonitrile
- Prior art date
Links
- 201000003793 myelodysplastic syndrome Diseases 0.000 title claims abstract description 95
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 64
- 239000003112 inhibitor Substances 0.000 title claims abstract description 50
- 101700034277 JAK1 Proteins 0.000 title claims abstract description 9
- 102100019517 JAK1 Human genes 0.000 claims abstract description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 70
- -1 6-chloropyridinyl Chemical group 0.000 claims description 68
- 239000011780 sodium chloride Substances 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 25
- 125000002393 azetidinyl group Chemical group 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 206010033661 Pancytopenia Diseases 0.000 claims description 19
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 17
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 16
- 210000003324 RBC Anatomy 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 210000003743 Erythrocytes Anatomy 0.000 claims description 13
- 102100019516 JAK2 Human genes 0.000 claims description 12
- 101700016050 JAK2 Proteins 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 208000009527 Refractory Anemia Diseases 0.000 claims description 11
- 239000003173 antianemic agent Substances 0.000 claims description 11
- 230000001419 dependent Effects 0.000 claims description 11
- 206010058314 Dysplasia Diseases 0.000 claims description 10
- 208000007502 Anemia Diseases 0.000 claims description 9
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 8
- 102100019518 JAK3 Human genes 0.000 claims description 8
- 101700007593 JAK3 Proteins 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 7
- 108010036949 Cyclosporine Proteins 0.000 claims description 7
- 108010008165 Etanercept Proteins 0.000 claims description 7
- 241000229754 Iva xanthiifolia Species 0.000 claims description 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 7
- 229960003433 Thalidomide Drugs 0.000 claims description 7
- 229960003603 decitabine Drugs 0.000 claims description 7
- 229960000403 etanercept Drugs 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 230000004044 response Effects 0.000 claims description 7
- 229960002756 Azacitidine Drugs 0.000 claims description 6
- 229940119017 Cyclosporine Drugs 0.000 claims description 6
- FVSKHRXBFJPNKK-UHFFFAOYSA-N Propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 claims description 6
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- 108010053490 Infliximab Proteins 0.000 claims description 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 5
- 101700057652 TYK2 Proteins 0.000 claims description 5
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims description 5
- 229960000598 infliximab Drugs 0.000 claims description 5
- 229960004942 lenalidomide Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 102100016864 TYK2 Human genes 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
- 241001243925 Sia Species 0.000 claims description 3
- 230000001494 anti-thymocyte Effects 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 229960000688 pomalidomide Drugs 0.000 claims description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010067959 Refractory cytopenia with multilineage dysplasia Diseases 0.000 claims description 2
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 3
- 108060003434 alpha Proteins 0.000 claims 1
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1H-pyrrolo[2,3-b]pyridine Chemical class C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 abstract 1
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 114
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
- 150000001875 compounds Chemical group 0.000 description 74
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
- 239000000047 product Substances 0.000 description 47
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 44
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- 201000010099 disease Diseases 0.000 description 36
- 239000000243 solution Substances 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 210000004027 cells Anatomy 0.000 description 27
- 125000000714 pyrimidinyl group Chemical group 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 21
- 239000012267 brine Substances 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reduced Effects 0.000 description 18
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000003394 haemopoietic Effects 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 239000008079 hexane Substances 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 238000004293 19F NMR spectroscopy Methods 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 10
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N Levofloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- 210000004369 Blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 8
- 210000001185 Bone Marrow Anatomy 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 238000004166 bioassay Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000002757 inflammatory Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 102100019388 SOAT1 Human genes 0.000 description 7
- 101700025022 SOAT1 Proteins 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 7
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 101710028406 satA Proteins 0.000 description 7
- 230000004083 survival Effects 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 6
- 210000001772 Blood Platelets Anatomy 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 230000001404 mediated Effects 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000000770 pro-inflamatory Effects 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 206010059512 Apoptosis Diseases 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 101700067048 CDC13 Proteins 0.000 description 5
- JMANVNJQNLATNU-UHFFFAOYSA-N Cyanogen Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 5
- 229960003957 Dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 241001182492 Nes Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000000973 chemotherapeutic Effects 0.000 description 5
- 230000000925 erythroid Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000002489 hematologic Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- PFBUKDPBVNJDEW-UHFFFAOYSA-N Dichlorocarbene Chemical group Cl[C]Cl PFBUKDPBVNJDEW-UHFFFAOYSA-N 0.000 description 4
- 229960004679 Doxorubicin Drugs 0.000 description 4
- 101710009074 FLT3 Proteins 0.000 description 4
- 102000015617 Janus Kinases Human genes 0.000 description 4
- 108010024121 Janus Kinases Proteins 0.000 description 4
- 102100017873 PTK2 Human genes 0.000 description 4
- 101700086523 PTK2 Proteins 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 102000018511 hepcidin family Human genes 0.000 description 4
- 108060003558 hepcidin family Proteins 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 description 3
- KVNRLNFWIYMESJ-UHFFFAOYSA-N Butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 206010065973 Iron overload Diseases 0.000 description 3
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 3
- 229960001021 Lactose Monohydrate Drugs 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001592 Paclitaxel Drugs 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 102000001253 Protein Kinases Human genes 0.000 description 3
- 108010078762 Protein Precursors Proteins 0.000 description 3
- 102000014961 Protein Precursors Human genes 0.000 description 3
- 101700007719 RAF1 Proteins 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 description 3
- 206010043554 Thrombocytopenia Diseases 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 102100013671 ZHX2 Human genes 0.000 description 3
- 101700069422 ZHX2 Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000003197 catalytic Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 101700021162 envZ Proteins 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 101710004466 rgy Proteins 0.000 description 3
- 101710030364 rgy1 Proteins 0.000 description 3
- 101710030359 rgy2 Proteins 0.000 description 3
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 3
- 229960000215 ruxolitinib Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 235000002374 tyrosine Nutrition 0.000 description 3
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZQQSYPZAPHRXRY-UHFFFAOYSA-N 1-hydroxyazetidine Chemical compound ON1CCC1 ZQQSYPZAPHRXRY-UHFFFAOYSA-N 0.000 description 2
- JSFATNQSLKRBCI-VAEKSGALSA-N 15-Hydroxyicosatetraenoic acid Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- VUGRPJUREUOUIO-UHFFFAOYSA-N 2H-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 VUGRPJUREUOUIO-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- KEJMSTJTAWACNI-UHFFFAOYSA-N 4-cyano-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1F KEJMSTJTAWACNI-UHFFFAOYSA-N 0.000 description 2
- 101700006234 AKT1 Proteins 0.000 description 2
- 229940028652 Abraxane Drugs 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N Boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229940121647 EGFR inhibitors Drugs 0.000 description 2
- 108091007936 ERK family Proteins 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N Ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N Fluocinolone acetonide Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 206010018987 Haemorrhage Diseases 0.000 description 2
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229940102213 Injectable Suspension Drugs 0.000 description 2
- 108010067319 Isoantibodies Proteins 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 229960001375 Lactose Drugs 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 2
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 210000003593 Megakaryocytes Anatomy 0.000 description 2
- MBABOKRGFJTBAE-UHFFFAOYSA-N Methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 2
- 229960004023 Minocycline Drugs 0.000 description 2
- 210000001616 Monocytes Anatomy 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 210000000066 Myeloid Cells Anatomy 0.000 description 2
- VMWJCFLUSKZZDX-UHFFFAOYSA-N N,N-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- QTTRZHGPGKRAFB-OOKHYKNYSA-N Rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 2
- 108010001645 Rituximab Proteins 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229920002397 Thermoplastic olefin Polymers 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102400000757 Ubiquitin Human genes 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 125000004429 atoms Chemical group 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000000740 bleeding Effects 0.000 description 2
- 231100000319 bleeding Toxicity 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 2
- 230000002559 cytogenic Effects 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 230000002380 cytological Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000000861 pro-apoptotic Effects 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Chemical compound [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl N-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
- 230000035921 thrombopoiesis Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 150000003668 tyrosines Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- FMCGSUUBYTWNDP-MWLCHTKSSA-N (1S,2R)-2-(dimethylamino)-1-phenylpropan-1-ol Chemical compound CN(C)[C@H](C)[C@@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-MWLCHTKSSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2R,3R)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- IJXJGQCXFSSHNL-MRVPVSSYSA-N (2S)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1,2,3-triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- HKQTYQDNCKMNHZ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)CCC21OCCO2 HKQTYQDNCKMNHZ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- WKMUUISSZDCMKG-UHFFFAOYSA-N 1H-[1,3]oxazolo[5,4-b]pyridine-2-thione Chemical compound C1=CN=C2OC(S)=NC2=C1 WKMUUISSZDCMKG-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-FIBGUPNXSA-N 2,2,2-trideuterioacetonitrile Chemical compound [2H]C([2H])([2H])C#N WEVYAHXRMPXWCK-FIBGUPNXSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(N-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- BAMUAAIPBLVVHU-UHFFFAOYSA-N 2-acetyl-2-acetyloxy-3-hydroxybutanedioic acid Chemical compound CC(=O)OC(C(O)=O)(C(C)=O)C(O)C(O)=O BAMUAAIPBLVVHU-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- DXRBTBMFFGEVCX-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)N=C1Cl DXRBTBMFFGEVCX-UHFFFAOYSA-N 0.000 description 1
- OMXMPMNUSMLQQS-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NC(C(F)(F)F)=C1 OMXMPMNUSMLQQS-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- GOYPFNAZTPCXGS-UHFFFAOYSA-N 3-fluoro-2-(trifluoromethyl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C(F)(F)F)=C1F GOYPFNAZTPCXGS-UHFFFAOYSA-N 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- XZLCRGQCOBHLJK-UHFFFAOYSA-N 4-[4-(2-hydroxypropan-2-yl)-6-(trifluoromethyl)pyridin-2-yl]oxycyclohexan-1-one Chemical compound FC(F)(F)C1=CC(C(C)(O)C)=CC(OC2CCC(=O)CC2)=N1 XZLCRGQCOBHLJK-UHFFFAOYSA-N 0.000 description 1
- FGWQQQAITPDCPA-BYPYZUCNSA-N 4-chloro-2,5-difluoro-N-[(2S)-1,1,1-trifluoropropan-2-yl]benzamide Chemical compound FC(F)(F)[C@H](C)NC(=O)C1=CC(F)=C(Cl)C=C1F FGWQQQAITPDCPA-BYPYZUCNSA-N 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- 101710037290 A674R Proteins 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 108010004463 Abciximab Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229940119059 Actemra Drugs 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- MGEVGECQZUIPSV-UHFFFAOYSA-N BOP reagent Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 MGEVGECQZUIPSV-UHFFFAOYSA-N 0.000 description 1
- 206010058956 Bicytopenia Diseases 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100009787 CABIN1 Human genes 0.000 description 1
- 108010066057 CABIN1 Proteins 0.000 description 1
- 102100012032 CCL20 Human genes 0.000 description 1
- 101700018681 CCL20 Proteins 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 210000003229 CMP Anatomy 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- XDRYWHWLVPAVKB-UHFFFAOYSA-M ClC=1C(=NC=C(N=1)C)C(=O)[O-] Chemical compound ClC=1C(=NC=C(N=1)C)C(=O)[O-] XDRYWHWLVPAVKB-UHFFFAOYSA-M 0.000 description 1
- UMTVBJZUGBXTLZ-UHFFFAOYSA-N ClC=1C2=C(N=C(N=1)COCC[Si](C)(C)C)NC=C2 Chemical compound ClC=1C2=C(N=C(N=1)COCC[Si](C)(C)C)NC=C2 UMTVBJZUGBXTLZ-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000000970 DNA cross-linking Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N Dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N Diatrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IWCWQNVIUXZOMJ-MISYRCLQSA-N Ecabet Chemical compound OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(S(O)(=O)=O)=C1 IWCWQNVIUXZOMJ-MISYRCLQSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- OLIMQRWLPHQWNH-UHFFFAOYSA-N FC(C1(NC=CC=N1)C(=O)O)(F)F Chemical compound FC(C1(NC=CC=N1)C(=O)O)(F)F OLIMQRWLPHQWNH-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 1
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- 229960001347 Fluocinolone Acetonide Drugs 0.000 description 1
- PJZDLZXMGBOJRF-CXOZILEQSA-L Folfirinox Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PJZDLZXMGBOJRF-CXOZILEQSA-L 0.000 description 1
- 208000008032 Gastrointestinal Hemorrhage Diseases 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 229920001386 Gefarnate Polymers 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061187 Haematopoietic neoplasm Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 240000006600 Humulus lupulus Species 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N Isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 102000036507 JAK family Human genes 0.000 description 1
- 108091020259 JAK family Proteins 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N L-Norpseudoephedrine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 102100006672 LACRT Human genes 0.000 description 1
- 101700077657 LACRT Proteins 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N Methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 210000004400 Mucous Membrane Anatomy 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- RIJLVEAXPNLDTC-UHFFFAOYSA-N N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical group C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N N-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N N-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- 229940073569 N-methylephedrine Drugs 0.000 description 1
- 125000000815 N-oxide group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 1
- 101710018405 PTPN11 Proteins 0.000 description 1
- 102100017818 PTPN11 Human genes 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241000146313 Parnassius apollo Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 229960000395 Phenylpropanolamine Drugs 0.000 description 1
- 102000029987 Phosphatidylethanolamine-binding protein Human genes 0.000 description 1
- 108091000043 Phosphatidylethanolamine-binding protein Proteins 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- KASDHRXLYQOAKZ-XDSKOBMDSA-N Pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 1
- 240000003524 Pinus torreyana Species 0.000 description 1
- 235000006235 Pinus torreyana Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004179 Plasminogen activator inhibitor-2 Human genes 0.000 description 1
- 108090000614 Plasminogen activator inhibitor-2 Proteins 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
- 229960001487 RIMEXOLONE Drugs 0.000 description 1
- 230000025458 RNA interference Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229940053174 Restasis Drugs 0.000 description 1
- 229940061341 Retisert Drugs 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N Rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 Rivoglitazone Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101710025702 SMARCA2 Proteins 0.000 description 1
- 102100019429 SMARCA2 Human genes 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N Santene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 101700026084 THY1 Proteins 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 102100008188 TYROBP Human genes 0.000 description 1
- 108060008723 TYROBP Proteins 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical group C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 229940055059 Vexol Drugs 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N Voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 229960005289 Voclosporin Drugs 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- GXJABQQUPOEUTA-NVXWUHKLSA-N [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-NVXWUHKLSA-N 0.000 description 1
- AVFUHBJCUUTGCD-UHFFFAOYSA-M [Br-].[Mg+]C Chemical compound [Br-].[Mg+]C AVFUHBJCUUTGCD-UHFFFAOYSA-M 0.000 description 1
- TWCMZOCNJQYFJV-UHFFFAOYSA-M [O-]C(=O)N1CC(=CC#N)C1 Chemical compound [O-]C(=O)N1CC(=CC#N)C1 TWCMZOCNJQYFJV-UHFFFAOYSA-M 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 102000035425 adaptor proteins Human genes 0.000 description 1
- 108091005736 adaptor proteins Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 230000000735 allogeneic Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 238000009166 antihormone therapy Methods 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- YCNIBOIOWCTRCL-UHFFFAOYSA-N azane;2,2,2-trifluoroacetic acid Chemical compound [NH4+].[O-]C(=O)C(F)(F)F YCNIBOIOWCTRCL-UHFFFAOYSA-N 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- PARZWJCTDFFJHI-UHFFFAOYSA-N benzyl 3-(2-cyanoethenyl)pyrrolidine-1-carboxylate Chemical compound C1CC(C=CC#N)CN1C(=O)OCC1=CC=CC=C1 PARZWJCTDFFJHI-UHFFFAOYSA-N 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 101700008534 brm Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000002281 colonystimulating Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 229940119350 dehydroepiandrosterone Drugs 0.000 description 1
- 230000001335 demethylating Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 229950003529 diquafosol Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- 229950003246 ecabet Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 108010010371 efalizumab Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 230000001973 epigenetic Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HXTBSJOGZDYEIO-UHFFFAOYSA-N ethyl 2-[3-(cyanomethyl)indol-1-yl]acetate Chemical compound C1=CC=C2N(CC(=O)OCC)C=C(CC#N)C2=C1 HXTBSJOGZDYEIO-UHFFFAOYSA-N 0.000 description 1
- BUBWTSJXUHKBBX-UHFFFAOYSA-N ethyl acetate;sodium Chemical compound [Na].CCOC(C)=O BUBWTSJXUHKBBX-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960003779 gefarnate Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 201000002138 hematopoietic system disease Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitors Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000003463 hyperproliferative Effects 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 101700028417 ins-3 Proteins 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- JHBZAAACZVPPRQ-UHFFFAOYSA-L lithium;magnesium;2,2,6,6-tetramethylpiperidin-1-ide;dichloride Chemical compound [Li+].[Cl-].[Cl-].CC1(C)CCCC(C)(C)N1[Mg+] JHBZAAACZVPPRQ-UHFFFAOYSA-L 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- CVVMLRFXZPKILB-UHFFFAOYSA-N methyl 5-chloropyrazine-2-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=N1 CVVMLRFXZPKILB-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 229940083353 mycophenolate sodium Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 101710039033 pkbA Proteins 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920003255 poly(phenylsilsesquioxane) Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- GKGFTIKPKGWMOW-UHFFFAOYSA-N propane-1,1,1-triolate Chemical compound CCC([O-])([O-])[O-] GKGFTIKPKGWMOW-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 231100001019 reduced numbers of red blood cells Toxicity 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000000580 secretagogue Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 101700064492 senju Proteins 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 102000003995 transcription factors Human genes 0.000 description 1
- 108090000464 transcription factors Proteins 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- XJTPJVZIHIUHNZ-UHFFFAOYSA-N trimethyl-[2-[(4-pyrazol-1-ylpyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl]silane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1N1C=CC=N1 XJTPJVZIHIUHNZ-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
This invention relates to JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, and their use in treating myelodysplastic syndromes (MDS).
Description
JAKl TORS FOR THE ENT OF MYELODYSPLASTIC
SYNDROMES
This application claims the benefit of priority of U.S. Prov. Appl. No.
61/946,124, filed February 28, 2014, which is incorporated herein by reference in its
entirety.
TECHNICAL FIELD
This invention s to JAKl selective inhibitors and their use in treating
myelodysplastic syndromes (MDS).
OUND
Myelodysplastic syndromes (MDS), known usly as dysmyelopoietic
syndromes or preleukemia, are heterogeneous and clonal hematopoietic disorders that
are characterized by ineffective hematopoiesis on one or more of the major myeloid
cell lineages. Myelodysplastic syndromes are associated with bone marrow failure,
peripheral blood cytopenias, and a propensity to progress to acute myeloid leukemia
(AML). Moreover, clonal cytogenetic alities can be detected in about 50% of
cases with MDS. In the l population, MDS occurs in 5 per 100,000 and the
incidence ses with age, reaching to about 22 to 45 per 100,000 in duals
older than 70 years (Greenberg, “The myelodysplastic syndromes” in Hoffman, et al,
eds. Hematology: Basic Principles and Practice (3rd ed.), Churchill ston;
2000: 1 106-1 129; Liesveld and Lichtman, Chapter 88. “Myelodysplastic Syndromes
(Clonal Cytopenias and Oligoblastic Myelogenous Leukemia)”, in Prchal et al, eds.
Williams Hematology. 8th ed., New York: McGraw-Hill; 2010). Despite scientific
advances in our knowledge of the pathophysiology of MDS, there are few therapeutic
options available and are mostly palliative, especially when affected patients are not
candidates for hematopoietic stem cell transplant (HSCT).
The standard of care for MDS includes supportive care that involves
observation and clinical monitoring, psychosocial support, and s to improve
QOL (Cheson, et al, Blood 2000;96:3671—3 674; Venugopal et al. Cancer Treat Res
2001;108:257—265; Greenberg, Int JPed Hem-One 1997;4:23 1—23 8). In addition,
RBC transfusions for symptomatic anemia and platelet transfusions for bleeding
episodes from thrombocytopenia are needed. Myelodysplastic syndrome patients
requiring RBC transfusions may develop complications ing development of
alloantibodies requiring increasing transfusion frequency, and iron overload with end—
organ damage to the liver, heart, and endocrine organs requiring helation to
maintain serum ferritin at < 1000 ug/L opal et al 2001 (supra), Greenberg
1997 (supra)). In cases with tory symptomatic cytopenia, hematopoietic
cytokine support is needed, such as the use of recombinant human granulocyte
colony-stimulating factor (G CSF) or granulocyte-monocyte CSF (GM—CSF) for
neutropenic MDS with infectious complications, and erythropoiesis-stimulating agent
(BSA) for symptomatic anemia (Cheson et al 2000 (supra), Jadersten et al, Blood
2005;106:803—81 1; Schiffer, Hematology Am Soc Hematol Educ Program 2006:205—
210). In early stage MDS, ie, IPSS low and IPSS Intermediate-1, symptomatic
anemia is the most common reason requiring therapeutic intervention. The ESA
benef1ts only a on of these patients with the highest response seen in patients
who are not RBC usion dependent or those with a low endogenous EPO level (<
500 IU) (Cheson et al 2000 (supra), ten et al 2005 ), Schiffer 2006
(supra), FenauX, et al., Lancet Oncol 2009;10:223—232). Eventually, patients stop
ding to BSA therapy and require RBC transfusion support, although ESA is
typically continued even when RBC transfusions are needed and reticulocyte counts
are low. Transfusion requirement may vary and may be influenced by concomitant
medical issues requiring a higher Hgb level such as angina, development of
alloantibodies to RBC, splenomegaly, and occult gastrointestinal hemorrhage from
thrombocytopenia or platelet ction (Venugopal et al 2001 (supra), Greenberg
1997 (supra), Fenaux et al 2009 (supra)).
Low-intensity y includes the use of low-intensity chemotherapy or
biological response modif1ers (BRM). Hypomethylating agents such as DNA
methyltransferase inhibitors 5 azacytidine and decitabine (5-aza—2’-deoxycytidine)
have been shown to reduce the risk of leukemic transformation in randomized Phase 3
studies and improve overall survival in a proportion of patients (Fenaux et al 2009
(supra), Silverman, J Clin Oncol 0:2429—2440; Silverman, J Clin Oncol
2006;24:3895—3 903). Similarly, decitabine has demonstrated a higher disease
response rate, on of remission, time to AML ssion, and survival benefit in
MDS patients with intermediate-risk and high risk disease. In addition, decitabine
demonstrated significant ement in patient-reported QOL (based on The
European Organisation for Research and Treatment of Cancer [EORTC QLQ C30])
for the dimensions of fatigue and al functioning (Kantarjian, et al., Cancer
2006; 106: 1794—1803; Liibbert, et al., Br JHaematoZ2001;114:349—357; Liibbert, et
al., J Clin 0ncol2011;29:l987—l996). Both 5—azacytidine and decitabine are
approved for MDS treatment and specifically provides clinical benefit and
recommended by the NCCN MDS panel for patients with IPSS intermediate 2 and
high-risk MDS (National hensive Cancer Network (NCCN). Myelodysplastic
Syndromes Guidelines Version 1. 2012.
www.nccn.org/professionals/physician_gls/f_guidelines.asp).
Inflammatory molecules have been implicated as regulatory cues driving the
proliferation and apoptotic death of hematopoietic progenitors in MDS. Chronic
immune stimulation, coupled with senescence dependent changes in both
hematopoietic stem/progenitor cells (HSPC) and the BM microenvironment, are
believed to be al to the pathogenesis of the disease. sing evidence
ates the activation of innate immune signaling in both hematopoietic
senescence and the pathobiology of MDS (Chen et al., 2014). As such, immune
modifiers that include T cell tors such as antithymocyte globulin (ATG),
cyclosporine, and thalidomide and its analog lenalidomide (Molldrem, et al., Br J
Haematol 9:699—705; , et al., JClin Oncol 2008;26:2505—2511; Raza, et
al., Blood 2008; l l 1:86—93; Fenaux, et al., Blood 2011;118:3765—3776; List, et al., N
Engl JMed 2005;352:549—557) are used as low intensity agents MDS. High—intensity
therapy for MDS include intensive induction chemotherapy, as is used for treating
AML and HSCT. Different ive chemotherapeutic regimens have been tested as
they have the potential for altering the natural history of the e and comparative
studies have failed to show benefit; this approach remains investigational and a
possible option for MDS patients with high-risk disease. Allogeneic HSCT, the only
curative treatment ty for MDS and preferably from a matched sibling donor, is
a preferred option for high-risk MDS patients, but the lack of a suitable donor and
comorbidities related to advancing age often preclude these patients from undergoing
this procedure (NCCN 2012 ); Larson, Best Pract Res Clin Hematol
2006;19:293—300; Schiffer, Best Pract Res Clin Hematol 2007;20:49—55).
Accordingly, there is a need to develop new therapies for the treatment of
myelodysplastic syndromes. This application addresses this need and others.
SUMMARY
The t application provides s of treating a myelodysplastic
syndrome (MDS) in a patient in need thereof, comprising administering to said patient
a therapeutically ive amount of a JAKl selective inhibitor, or a pharmaceutically
acceptable salt thereof.
The present application further provides a JAKl selective inhibitor for the
treatment of a myelodysplastic syndrome in a patient in need thereof.
The present application also provides use of a JAKl selective inhibitor for
manufacture of a medicament for use in treatment of a myelodysplastic syndrome in a
patient in need thereof.
DETAILED DESCRIPTION
The methods bed herein utilize JAKl selective inhibitors. A JAKl
selective inhibitor is a compound that ts JAKl activity preferentially over other
Janus s. JAKl plays a central role in a number of cytokine and growth factor
signaling pathways that, when dysregulated, can result in or contribute to disease
states. For example, IL-6 levels are elevated in rheumatoid arthritis, a e in
which it has been ted to have detrimental effects (Fonesca, et al., Autoimmunity
Reviews, 8:538—42, 2009). Because IL-6 signals, at least in part, through JAKl,
antagonizing IL-6 directly or indirectly through JAKl inhibition is expected to
provide clinical benefit (Guschin, et al Embo J 14: 1421, 1995; Smolen, et al. Lancet
371 :987, 2008). Moreover, in some cancers JAKl is mutated resulting in constitutive
undesirable tumor cell growth and survival (Mullighan, Proc Natl Acad Sci U S
A. 106:9414—8, 2009; Flex, JExp Med. 205:751—8, 2008). In other autoimmune
diseases and s ed systemic levels of inflammatory cytokines that activate
JAKl may also contribute to the disease and/or associated symptoms. ore,
patients with such es may benefit from JAKl inhibition. Selective inhibitors of
JAKl may be efficacious while ng unnecessary and potentially undesirable
effects of inhibiting other JAK kinases.
Selective inhibitors of JAKl, relative to other JAK kinases, may have multiple
therapeutic advantages over less selective inhibitors. With respect to selectivity
against JAK2, a number of important cytokines and growth factors signal through
JAK2 including, for example, erythropoietin (Epo) and thrombopoietin (Tpo)
(Parganas, et al. Cell. 93:385—95, 1998). Epo is a key growth factor for red blood
cells production; hence a paucity of Epo—dependent signaling can result in reduced
numbers of red blood cells and anemia (Kaushansky, NEJM 354:2034—45, 2006).
Tpo, another example of a JAK2-dependent growth factor, plays a central role in
controlling the proliferation and maturation of megakaryocytes — the cells from which
platelets are produced (Kaushansky, NEJM 354:2034—45, 2006). As such, d
Tpo signaling would decrease megakaryocyte numbers aryocytopenia) and
lower circulating platelet counts bocytopenia). This can result in undesirable
and/or uncontrollable bleeding. Reduced inhibition of other JAKs, such as JAK3 and
Tyk2, may also be ble as humans lacking functional n of these kinases
have been shown to suffer from numerous maladies such as severe—combined
immunodeflciency or hyperimmunoglobulin E syndrome (Minegishi, et al. Immunity
:745—55, 2006; Macchi, et al. Nature, 377:65—8, 1995). Therefore a JAKl inhibitor
with d affinity for other JAKs would have significant advantages over a less—
selective inhibitor with respect to reduced side effects involving immune suppression,
anemia and thrombocytopenia.
Inflammatory cytokines play a significant role in the pathogenesis of MDS,
which results in cytopenias and dysplastic poiesis. It is hypothesized that
curbing the activity of these inflammatory cytokines will promote normal
hematopoiesis and relieve the marrow sors from premature apoptosis. The
inflammatory cytokines mediate downstream s by JAK activation which
involves juxtapositioning of JAKs from ligand-mediated receptor dimerization and
trans/autophosphorylation. The resultant JAK heterodimers, comprised of JAKl and
JAK2 or JAKl and JAK3, transduce signals and mediate cellular responses of these
nes. Moreover, JAK homodimers, comprised of only JAK2, transduce s
from bone marrow growth factors such as EPO, which is sible for stimulating
erythropoiesis, and TPO, which is responsible for stimulating thrombopoiesis.
Therefore, a selective JAKl inhibitor would result in abrogation of the inflammatory
cytokine signaling without inhibiting JAKZ-mediated erythropoiesis and
thrombopoiesis, resulting in the reestablishment of normal hematopoiesis and
alleviation of myeloid cytopenias.
Despite scientific es in our knowledge of the pathophysiology of MDS,
there are few therapeutic options ble and are mostly palliative, especially when
affected patients are not candidates for HSCT. A number of studies have indicated
that MDS is a clonal disease and demonstrated that the expanded clone was a result of
excessive proliferation of hematopoietic itors in the bone marrow. The
paradox of a hyperproliferative state in the marrow leading to peripheral cytopenias
was investigated and revealed that there was an ive amount of intramedullary
programmed cell death or apoptosis of the hematopoietic cells. This sis was
seen in patients with all the FAB categories but decreased in ts with increasing
blast counts. It appeared that a clonal population progressively became resistant to
apoptosis and gained a proliferative advantage over the normal hematopoietic
precursors that led to the increase in blast counts and evolution to AML. It also
became evident that the excessive apoptosis was largely mediated by a number of
proinflammatory cytokines that are pressed in the marrows of patients with
MDS. The cytokines that have been implicated in the pathobiology of MDS e
tumor necrosis factor-alpha (TNF-0t), interferon-gamma (IFN y) and IL 18. High
plasma concentration of TNF—0t, a c proapoptotic cytokine, has been observed in
the peripheral blood and the bone marrow of patients with MDS and a higher
expression of TNF receptors and messenger ribonucleic acid (mRNA) has been
observed in bone marrow mononuclear cells derived from MDS patients. Similarly,
an increased amount of IFN y and IL 18 has been found in MDS bone marrow
mononuclear cells and IL-lB has been implicated in the ion of AML from
MDS. The IL-lB has le regulatory effects on the hematopoietic cells as it
stimulates GM-CSF and IL-3, whereas in higher trations as seen in
inflammatory states, it leads to suppression of hematopoiesis by induction of TNF 0t
and prostaglandin E2, the latter being a potent suppressor of myeloid stem cell
proliferation. In addition, high levels of IL-6, fibroblast growth factor, hepatocyte
growth factor, and transforming growth factor B has been seen in myeloid cells from
MDS patients. Moreover, the very nes that suppress the normal hematopoietic
proliferation and maturation fail to exert this proapoptotic effect on the evolving
abnormal clone that results in selective proliferation of these abnormal cells. There is
evidence that the source of these proinflammatory nes is the altered bone
marrow microenvironment that normally nurtures the normal hematopoietic cells to
proliferate and differentiate, and may also be the reason for the ration of immune
regulatory cells and angiogenesis that contributes to the pathobiology of MDS (Raza,
et al., Blood 1995;86:268—276; Raza, et al, Int JHematol l996a;63:265—278; Raza, et
al., Leuk Res l996b;20:881—890; Mundle, et al. Am JHematol 0:36—47;
Claessens, et al., Blood 2002;99:1594—1601).
The concept that the cytokine-mediated proinflammatory state is responsible
for the etiology of MDS has led to the novel approach of anticytokine therapy to
improve the cytopenias in MDS by ting the differentiating hematopoietic cells
from premature apoptosis. There has been demonstration that anti—TNF-(x agents like
thalidomide and its analog lenalidomide, infliximab, and etanercept have been
effective in improving cytopenias in MDS patients (NCCN 2012 (supra), Larson 2006
(supra), Schiffer 2007(supra)). In a study of 14 MDS patients, etanercept showed
erythroid hematologic ement in 25% of patients along with improvement in
platelet counts and ANC in 12.5% of evaluable patients. Additionally combining
intermittent etanercept with ATG ed in a higher erythroid hematologic
improvement and 5 of the 14 MDS patients requiring transfusion became RBC and
et transfusion independent that lasted beyond 2 years. In a study investigating
thalidomide in MDS, of the 83 patients enrolled, 51 completed 12 weeks of therapy
and 16 patients showed hematologic improvement with 10 previously usion-
dependent patients becoming transfusion independent and most of the responders
were in either the IPSS low-risk or intermediate 1 risk category (NCCN 2012
(supra)). Moreover, higher risk category patients, especially with a high blast
percentage, tended to discontinue treatment early. Another approach to curb the
s of the proinflammatory nes is to t their cellular responses. A
considerable number of cytokine and growth factor receptors utilize the JAK family
of nonreceptor TYKs to transmit extracellular ligand binding into a cellular response
via the transcription factor STAT signaling.
There are 4 s of JAKs: JAKl, JAKZ, JAK3, and TYK2. The JAKs
are constitutively associated with cytokine and growth factor receptors and have
become activated as an immediate consequence of ligand—induced receptor
dimerization, JAK activation occurs upon the subsequent juxtapositioning of the
JAKs and the trans/autophosphorylation of conserved tyrosines found in the activation
loop of the JAK catalytic domain. Upon phosphorylation of these tyrosines, the JAKs
enter a high—activity state and are then able to phosphorylate lc tyrosine residues
on the ne receptors, which serve as docking sites for multiple proteins,
including the STAT proteins. The JAKs are the principal family of kinases associated
with STAT activation. ted STATs translocate to the nucleus where they
on as transcription factors and drive the expression of multiple genes important
for cell activation, localization, survival, and proliferation.
Ruxolitinib, a JAKl and JAKZ tor has trated marked reduction in
spleen size in patients with myelof1brosis and improvement of symptoms. These
improvements were apparent in subjects with and without the presence of the V617F
mutation in JAKZ and are likely related to inhibition of proinflammatory cytokines.
The primary e events (AEs) observed with ruxolitinib are ocytopenia
and anemia; both were infrequently the cause of study discontinuation in a double—
blind, placebo—controlled Phase 3 study, and both are due at least in part to JAK2—
mediated myelosuppression. It is therefore hypothesized that selective tion of
JAKl would exert a salutary effect of inhibiting proinflammatory cytokines in
patients with MDS and result in the amelioration of the cytopenias resulting from
premature apoptosis of the hematopoietic precursors. Moreover, sparing of JAK2
activity would allow the logical activity of hematopoietic cytokines namely
EPO and TPO to allow physiological proliferation and differentiation of the normal
hematopoietic cells.
Further, iron overload frequently occurs in MDS patients, with recent data
ting an impact on both overall and leukemia-free survival. It has been
postulated that an altered production of hepcidin, the recently discovered key
hormone regulating iron homeostasis, may play a role in this regard and be regulated
by inflammatory nes like IL-6. It has recently been shown in MDS that both
hepcidin and CRP, as a marker of general inflammation, are elevated. Santini, et al.,
PLoS One, 6(8), e23109, pages 1—8 (2011). These data suggest that JAK inhibition,
which can reduce CRP and hepcidin levels, may e the ation and iron
overload that occurs in MDS.
Accordingly, the present application provides, inter alia, a method of ng
a ysplastic syndrome in a patient in need thereof, comprising administering to
said patient a therapeutically effective amount of a JAKl selective inhibitor, or a
pharmaceutically acceptable salt thereof. As used herein, a myelodysplastic syndrome
refers to the classification of MDS proposed by the World Health Organization in
2008 (see e. g., Table 1). In particular, in 1997, the World Health Organization (WHO)
in conjunction with the Society for Hematopathology (SH) and the European
ation of Hematopathology (EAHP) proposed new classifications for
hematopoietic neoplasms (Harris, et al., J Clin Oncol 1999;17:3 83 5—3 849; Vardiman,
et al., Blood 2002;100:2292-2302). For MDS, the WHO utilized not only the
morphologic ia from the French-American-British (FAB) classification but also
incorporated available c, ic, and clinical characteristics to define subsets
of MDS (Bennett, et al., Br JHaematol 1982;51:189—199). In 2008, the WHO
classification of MDS (Table 1) was further refined to allow precise and
prognostically relevant subclassification of unilineage sia by incorporating new
clinical and scientific information (Vardiman, et al., Blood 2009;114:937—95 1;
Swerdlow, et al., WHO Classification of Tumours of Haematopoietic and Lymphoid
Tissues. 4th Edition. Lyon France: IARC Press; 2008:88-103; Bunning and Germing,
“Myelodysplastic syndromes/neoplasms” in Chapter 5, Swerdlow, et al, eds. WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues. (ed. 4th n):
Lyon, France: LARC Press;2008:88—103).
Table 1: 2008 WHO fication for De Novo Myelodysplastic Syndrome
Refractory cytopenia With
Dysplasia in 2 10% of 1 cell
unilineage dysplasia Single or Bicytopenia
line, < 5% blasts
(RCUD)
2 15% of erythroid precursors
Refractory anemia With
Anemia, no blasts W/ring sideroblasts, erythroid
ring sideroblasts (RARS)
dysplasia only, < 5% blasts
Dysplasia in 2 10% of cells in
Refractory cytopenia With Cytopenia(s), < 1 X 109/L 2 2 hematopoietic lineages, ::
multilineage dysplasia monocytes 15% ring sideroblasts, < 5%
blasts
Cytopenia(s), S 2% to Unilineage or ineage
Refractory anemia With
4% blasts, < 1 X 109/L dysplasia, No Auer rods, 5% to
excess blasts-1 l)
monocytes 9% blasts
Cytopenia(s), S 5% to Unilineage or multilineage
Refractory anemia With
19% blasts, < 1 x 109/L dysplasia, :: Auer rods, 10% to
excess blasts-2 (RAEB-Z)
tes 19% blasts
Unilineage or no dysplasia but
Myelodysplastic syndrome,
Cytopenias characteristic MDS
sified (MDS-U)
cytogenetics, < 5% blasts
MDS associated With Anemia, platelets normal Unilineage erythroid. Isolated
isolated del(5q) or increased ), < 5% blasts
In some embodiments, the JAKl selective inhibitor is selective for JAKl over
JAK2, JAK3, and TYK2. For example, the compounds described , or a
pharmaceutically able salt f, preferentially inhibit JAKl over one or more
of JAKZ, JAK3, and TYK2. In some embodiments, the compounds inhibit JAKl
preferentially over JAK2 (e.g., have a AKZ IC50 ratio >1). In some
embodiments, the compounds or salts are about lO—fold more selective for JAKl over
JAK2. In some embodiments, the compounds or salts are about 3—fold, about 5—fold,
about lO—fold, about lS—fold, or about 20—fold more selective for JAKl over JAKZ as
calculated by measuring IC50 at 1 mM ATP (e. g., see Example A).
In some embodiments, the JAKl selective inhibitor is a compound of Table 2,
or a pharmaceutically acceptable salt thereof.
Table 2
Prep in Name Structure JAK 1 JAKZ/
EX. No. IC50 JAKl
(11M)
18. 3 -chlor0pyridin
y1)pyrrolidin-3 -y1] -3 - [4-
(7H-pyrr010[2,3 -
midiny1)- 1 H-
pyrazolyl]pr0panenitrile
3 -(1-[1,3]0xazolo[5,4-
b]pyridinylpyrrolidin-3 -
y1) [4-(7H-pyrr010 [2,3-
d]pyrimidiny1)- 1 H-
pyrazolyl]pr0panenitrile
4- [(4- {3 -cyan0-2 - [4-(7H-
pyrr010[2 ,3-d]pyrimidin N N
y1)-1H-pyrazol \ , CN
yl]pr0py1}piperazin-1 -
yl)carb0nyl] -3 -
fluorobenzonitrfle NC
4- [(4- {3 -cyan0-2 - [3 -(7H-
pyrr010[2 ,3-d]pyrimidin
yl)-1H-pyrr01
yl]pr0py1}piperazin-1 -
yl)carb0nyl] -3 -
fluorobenzonitrfle
Prep in Name Structure
EX. N0.
[3-Fluor0 / N
(trifluoromethyl)isonicotino |
O \
yl]piperidinyl}[4- CF3
(7H-pyrr010[2,3- N F
d]pyrimidiny1)- 1 H-
pyrazoly1]azetidin-3 -
yl } acetonitrile
Q/jN
N — N
NI \ \
N/ E
6 4- { 3-(Cyanomethyl)-3 -[4- F
(7H-pyrr010[2,3 -
d]pyrimidiny1)- 1 H-
pyrazoly1]azetidin-1 -y1} - CF3
N-[4-fluor0
O N H
(trifluoromethyl)pheny1]pip Y
eridinecarb0xamide RNj
[)1 ‘N
“m \ \
7 [3-[4-(7H-pyrr010[2,3- O
d]pyrimidinyl)-1H- WN—
pyrazol-l-yl]—1-(1-{[2- N N—<
oromethyl)pyrimidin- < > CF3
4-y1]carbonyl }piperidin
y1)azetidiny1]acet0nitrile
N—NEN/N//
”C l \
Prep in Name Structure
EX. N0.
8 [trans-l-[4-(7H- F
pyrr010[2,3-d]pyrimidin F
y1)- 1H-pyrazol-1 -y1](4- , N
{ [2- N \
(trifluoromethyl)pyrimidin- o
4-yl]carb0nyl}piperazin-1 - N
y1)cyclobuty1]acetonitrfle (\ 3
I, /
I)! 'N
Nt \
N N
9 {trans(4-{[4-[(3- OH
hydroxyazetidin lj
yl)methy1]—6- N
(trifluoromethyl)pyridin
}piperidinyl) / \
[4-(7H-pyrr010[2,3 - \N F
d]pyrimidinyl)—1H- 0 F
pyrazol-l -
yl]cyclobuty1} acetonitrile
. I I /
N ' N
”m /
N N\
Prep in Name Structure
EX. N0.
{trans(4-{[4-{[(ZS)
xymethyl)pyrrolidiny1]methy1} Q
(trifluoromethyl)pyridin-2 - / \
}piperidinyl) \
[4-(7H-pyrr010[2,3- N F
O F
d]pyrimidiny1)- 1 H-
pyrazol-l - O
yl]cyclobuty1} acetonitrfle [\l
. . . /
N ' N
Nt /
N N‘
11 {trans(4-{[4-{[(2R)
(hydroxymethyl)pyrrolidin-
1 thy1} R
(trifluoromethyl)pyridin / \
yl]0xy}piperidinyl) \
[4-(7H-pyrr010[2,3- N F
O F
d]pyrimidiny1)- 1 H-
pyrazol-l - O
yl]cyclobuty1} acetonitrfle [\i
. . . /
N ' N
12b 4-(4-{3- >10
[(dimethylamin0)methyl] flu0r0phenoxy }piperidin-
1-y1)-3 -[4-(7H-pyrr010[2,3 -
d]pyrimidiny1)- 1 H-
pyrazoly1]butanenitrile
Prep in Name Structure JAKZ/
EX. No. JAK1
13 5 - {3 -(cyan0methy1)—3 - [4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
ly1]azetidin-1 -y1} -
N-isopropylpyrazine-Z -
carboxamide
14 4- {3 -(cyan0methy1)-3 - [4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
ly1]azetidin-1 -y1} -
2,5 -diflu0r0-N-[(1S)-2,2,2-
trifluoro
methylethy1]benzamide
5 - {3 -(cyan0methy1)—3 - [4- >10
(1 010[2,3 -b]pyridin-
4-y1)-1H-pyrazol
y1]azetidiny1}-N-
isopropylpyrazine-Z-
carboxamide
16 {1-(cz's { [6-(2-
hydroxyethy1)
(trifluoromethy1)pyrimidin-
xy}cy010hexy1)-3 - [4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
pyrazoly1]azetidin-3 -
y1}acetonitrile
17 {1-(cz's { [4-
[(ethy1amino)methy1]
(trifluoromethy1)pyridin-2 -
y1]0xy}cy010hexy1)[4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
pyrazoly1]azetidin-3 -
y1}acetonitrile
Prep in Name ure
EX. No.
18 {1-(cz's{[4-(1-hydr0xy
methylethy1)
(trifluoromethy1)pyridin-2 -
y1]0xy}cyclohexy1)[4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
pyrazoly1]azetidin-3 -
y1}acetonitrile
19 {1-(cz's { [4- { [(3R)—3-
hydroxypyrrolidin
y1]methy1}
(trifluoromethy1)pyridin-2 -
y1]0xy}cyclohexy1)[4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
pyrazol- 1 etidin-3 -
y1}acetonitrile
{1-(cz's { [4- { [(3 S)-3 -
hydroxypyrrolidin
hy1}
(trifluoromethy1)pyridin-2 -
y1]0xy}cyclohexy1)[4-
(7H-pyrr010[2,3 -
d]pyrimidiny1)-1H-
pyrazoly1]azetidin-3 -
y1}acetonitrile
Prep in Name Structure
EX. N0.
21 (4-{[4-({[(IS) OH
hydroxy-l - \{II
methylethyl]amin0}methyl)
(triflu0r0methyl)pyridin-
2-y1]0xy}piperidiny1) \ F
[4-(7H-pyrr010[2,3- ‘N F
o F
d]pyrimidinyl)—1H-
pyrazol-l -
yl]cyclobuty1} acetonitrfle ON
. I I /”N
N 'N
”m \
N N
22 (4-{[4-({[(2R)
hydroxypropyl]amino}meth OH
”'6'
(trifluoromethyl)pyridin
yl]0xy}piperidinyl)
[4-(7H-pyrr010[2,3- \ F
d]pyrimidiny1)- 1 H- N F
O F
pyrazol-l -
yl]cyclobuty1} acetonitrfle b
91/N//
N 'N
”m \
N N
Prep in Name ure
EX. N0.
23 {trans(4-{[4-({[(ZS) E
hydroxypropyl]amino}meth fOH
”'6'
(trifluoromethyl)pyridin
yl]oxy}piperidin-l -yl)- l -
[4-(7H-pyrrolo[2,3- \ F
d]pyrimidinyl)-1H- ‘N F
O F
pyrazol-l -
yl] cyclobutyl} acetonitrile O
9 /”N. I I
N 'N
le \
N N
24 (4-{[4-(2- HO
hydroxyethyl)
(trifluoromethyl)pyridin
yl]oxy}piperidin-l -yl)-l- / \ F
[4-(7H-pyrrolo[2,3 - \
d]pyrimidinyl)-1H- N
o F
pyrazol-l -
yl]cyclobutyl} acetonitrile
Q,/’N/
N 'N
N \
k| N/
+ means <10 nM (see Example A for assay conditions)
aData for enantiomer l
bData for enantiomer 2
In some embodiments, the JAKl ive inhibitor is {l- { l-[3 -Fluoro
(trifluoromethyl)isonicotinoyl]piperidinyl} [4-(7H-pyrrolo[2,3-d]pyrimidin
yl)— lH-pyrazol- l -yl]azetidin-3 -yl} acetonitrile adipic acid salt.
In some embodiments, the JAKl selective inhibitor is selected from (R)[l-
oropyridinyl)pyrrolidin-3 -yl][4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-
pyrazolyl]propanenitrile, (R)-3 -(1-[1,3]oxazolo[5 ,4-b]pyridinylpyrrolidin-3 -yl)[4-(7H-pyrrolo[2,3 -d]pyrimidinyl)-1H-pyrazolyl]propanenitrile, (R) [(4- {3 -
cyano [4-(7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazolyl]propyl}piperazin
yl)carbonyl]fluorobenzonitrile, (R)[(4- {3-cyano[3-(7H-pyrrolo[2,3-
d]pyrimidinyl)—1H-pyrrolyl]propyl}piperazinyl)carbonyl]—3 -
fluorobenzonitrile, or (R)(4-{3-[(dimethylamino)methyl]
fluorophenoxy}piperidinyl)-3 - [4-(7H-pyrrolo[2,3 -d]pyrimidinyl)-1H-pyrazol
yl]butanenitrile; or a pharmaceutically acceptable salt of any of the aforementioned.
In some embodiments, the JAKl selective inhibitor is selected from (S)—3—[1-
(6-chloropyridinyl)pyrrolidin-3 -yl]—3-[4-(7H-pyrrolo[2,3-d]pyrimidinyl)— 1H-
pyrazolyl]propanenitrile, (S)-3 -(1-[1,3]oxazolo[5 ,4-b]pyridinylpyrrolidin-3 -yl)[4-(7H-pyrrolo[2,3 -d]pyrimidinyl)-1H-pyrazolyl]propanenitrile, (S)[(4- {3 -
cyano [4-(7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazolyl]propyl}piperazin
yl)carbonyl]—3 -fluorobenzonitrile, (S)[(4- {3-cyano[3-(7H-pyrrolo[2,3-
d]pyrimidinyl)—1H-pyrrolyl]propyl}piperazinyl)carbonyl]—3 -
fluorobenzonitrile, or (S)(4- {3 -[(dimethylamino)methyl]
fluorophenoxy}piperidinyl)-3 - [4-(7H-pyrrolo[2,3 -d]pyrimidinyl)-1H-pyrazol
anenitrile; or a pharmaceutically able salt of any of the aforementioned.
In some embodiments, the JAKl selective tor is GLPG0634
(Galapagos).
In some embodiments, the compounds of Table 2 are prepared by the synthetic
procedures described in US Patent Publ. No. 2010/02983 34, filed May 21, 2010, US
Patent Publ. No. 2011/0059951, filed August 31, 2010, US Patent Publ. No.
2011/0224190, filed March 9, 2011, US Patent Publ. No. 2012/0149681, filed
November 18, 2011, US Patent Publ. No. 2012/0149682, filed November 18, 2011,
US Patent Publ. 2013/0018034, filed June 19, 2012, US Patent Publ. No.
2013/0045963, filed August 17, 2012, and US Patent Publ. No. 005166, filed
May 17, 2013, each of which is orated herein by reference in its ty.
In some embodiments, the JAKl tor is selected from the compounds of
US Patent Publ. No. 2010/02983 34, filed May 21, 2010, US Patent Publ. No.
2011/0059951, filed August 31, 2010, US Patent Publ. No. 2011/0224190, filed
March 9, 2011, US Patent Publ. No. 2012/0149681, filed November 18, 2011, US
Patent Publ. No. 2012/0149682, filed November 18, 2011, US Patent Publ.
2013/0018034, filed June 19, 2012, US Patent Publ. No. 2013/0045963, filed August
17, 2012, and US Patent Publ. No. 2014/0005166, filed May 17, 2013, each of which
is incorporated herein by nce in its entirety.
In some embodiments, the myelodysplastic syndrome is refractory cytopenia
with unilineage dysplasia (RCUD).
In some embodiments, the myelodysplastic me is refractory anemia
with ring sideroblasts (RARS).
In some embodiments, the myelodysplastic syndrome is refractory cytopenia
with multilineage dysplasia.
In some embodiments, the myelodysplastic syndrome is refractory anemia
with excess blasts—1 (RAEB-l).
In some embodiments, the myelodysplastic syndrome is refractory anemia
with excess blasts—2 (RAEB-2).
In some embodiments, the myelodysplastic syndrome is myelodysplastic
me, unclassified (MDS—U).
In some embodiments, the myelodysplastic me is myelodysplastic
syndrome associated with ed del(5q).
In some embodiments, the myelodysplastic syndrome is refractory to
erythropoiesis-stimulating agents (ESAs). In some embodiments, refractory to ESAs
means no improvement in Hgb of at least 1.5 g/dL after 8 weeks of at least 40,000
IU/week of opoietin (EPO) (or equivalent).
In some embodiments, the patient is red blood cell (RBC) transfusion
dependent. In some embodiments, red blood cell transfusion dependent means the
t requires at least 4 units of packed RBCs for a Hgb of < 9 g/dL over the 8
weeks prior to treatment.
In some embodiments, the patient has elevated serum hepcidin levels as
compared to a control group of healthy duals. In some ments, the patient
has an elevated serum c-reactive n (CRP) concentration as compared to a
control group of healthy individuals. In some embodiments, an elevated serum
concentration of CRP is one that is equal to or greater than about 10 ug/mL. In some
embodiments, healthy individuals are as defined in Santini, et al., PLOS One, 6(8),
e23109, pages 1—8 (2011), which is incorporated herein by reference in its entirety.
In some ments, the t has a modified Glasgow Prognostic Score of
1 or 2. The modified Glasgow Prognosis Score (GPS) is described in McMillian,
Cancer Treatment Reviews, 39 (5):534—540 (2013), which is incorporated herein by
nce in its ty (and in particular, the scores as shown in Table 1).
In some embodiments, the t invention provides a nd bed
herein, or a pharmaceutically acceptable salt thereof, as described in any of the
embodiments herein, for use in a method of treating any of the diseases or disorders
described herein. In some embodiments, the present invention provides the use of s a
compound described herein, or a pharmaceutically acceptable salt thereof, as
described in any of the embodiments herein, for the preparation of a ment for
use in a method of treating any of the diseases or disorders described herein.
The JAKl selective inhibitors also e pharmaceutically acceptable salts
of the compounds described herein. As used herein, aceutically acceptable
salts" refers to derivatives of the sed nds wherein the parent compound
is modified by converting an existing acid or base moiety to its salt form. Examples of
pharmaceutically acceptable salts include, but are not limited to, mineral or organic
acid salts of basic residues such as amines; alkali or organic salts of acidic residues
such as carboxylic acids; and the like. The pharmaceutically acceptable salts include
the non-toxic salts of the parent compound formed, for example, from non-toxic
inorganic or organic acids. The pharmaceutically acceptable salts can be synthesized
from the parent nd which contains a basic or acidic moiety by conventional
chemical methods. Generally, such salts can be prepared by reacting the free acid or
base forms of these compounds with a stoichiometric amount of the appropriate base
or acid in water or in an organic solvent, or in a mixture of the two; generally, non-
aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-
propanol, or butanol) or acetonitrile (ACN) are red. Lists of suitable salts are
found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company,
Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each
of which is incorporated herein by reference in its entirety. In some embodiments, the
compounds described herein include the N—oxide forms.
The nds described herein can be asymmetric (e.g., having one or more
stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended
unless otherwise indicated. Compounds described herein that contain asymmetrically
substituted carbon atoms can be ed in optically active or racemic forms.
Methods on how to prepare optically active forms from optically inactive starting
materials are known in the art, such as by resolution of racemic es or by
stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and
the like can also be present in the compounds described herein, and all such stable
isomers are contemplated in the present invention. Cis and trans geometric isomers of
the compounds of the present invention are described and may be isolated as a
mixture of isomers or as separated isomeric forms.
Resolution of racemic mixtures of compounds can be d out by any of
numerous methods known in the art. An example method includes fractional
recrystallizaion using a chiral resolving acid which is an optically , salt-forming
organic acid. Suitable ing agents for fractional recrystallization s are, for
example, optically active acids, such as the D and L forms of tartaric acid,
diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or
the various optically active rsulfonic acids such as B—camphorsulfonic acid.
Other ing agents suitable for onal crystallization methods include
stereoisomerically pure forms of OL-methylbenzylamine (e.g., S and R forms, or
diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-
methylephedrine, cyclohexylethylamine, l,2—diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column
packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
Suitable elution solvent composition can be determined by one skilled in the art.
Compounds described herein also e tautomeric forms. Tautomeric forms
result from the swapping of a single bond with an adjacent double bond together with
the concomitant migration of a proton. Tautomeric forms include ropic
tautomers which are isomeric protonation states having the same cal formula
and total charge. Example prototropic tautomers include ketone — enol pairs, amide —
imidic acid pairs, lactam — lactim pairs, e — imine pairs, and annular forms
where a proton can occupy two or more positions of a heterocyclic system, for
example, 1H- and 3H-imidazole, lH-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H-
isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or
sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all es of atoms occurring
in the intermediates or final nds. Isotopes e those atoms having the
same atomic number but different mass numbers. For example, isotopes of hydrogen
include deuterium.
The term, “compound,” as used herein is meant to include all stereoisomers,
geometric iosomers, tautomers, and isotopes of the structures depicted. Further,
compounds herein identified by name or structure as one particular tautomeric form
are intended to include other tautomeric forms unless otherwise ied.
All compounds, and ceutically acceptable salts thereof, can be found
together with other substances such as water and ts (e. g., hydrates and solvates)
or can be isolated.
In some embodiments, the compounds bed herein, or salts thereof, are
substantially isolated. By “substantially isolated” is meant that the compound is at
least partially or substantially separated from the environment in which it was formed
or ed. Partial separation can include, for example, a ition enriched in the
compounds of the invention. Substantial separation can include compositions
containing at least about 50%, at least about 60%, at least about 70%, at least about
80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%
by weight of the compounds of the invention, or salt thereof Methods for isolating
compounds and their salts are routine in the art.
As used herein, the term “individual” or “patient,” used interchangeably,
refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits,
dogs, cats, swine, cattle, sheep, horses, or es, and most preferably humans.
As used herein, the phrase “therapeutically effective ” refers to the
amount of active compound or ceutical agent that elicits the biological or
medicinal response that is being sought in a tissue, system, animal, individual or
human by a researcher, veterinarian, medical doctor or other clinician. In some
embodiments, the therapeutically effective amount is about 1 mg to about 100 mg,
about 1 mg to about 20 mg, about 4 mg to about 10 mg, about 5 mg to about 1000 mg,
or about 10 mg to about 500 mg. In some embodiments, the therapeutically effective
amount is 4 mg, 6 mg, or 10 mg QD.
The phrase “pharmaceutically acceptable” is employed herein to refer to those
compounds, als, compositions, and/or dosage forms which are, within the scope
of sound medical nt, suitable for use in contact with the tissues of human
beings and animals without excessive toxicity, tion, allergic response, or other
problem or complication, surate with a reasonable benefit/risk ratio.
As used herein, the term “treating” or “treatment” refers to one or more of (l)
preventing the disease; for e, preventing a disease, condition or disorder in an
individual who may be predisposed to the disease, condition or disorder but does not
yet experience or display the pathology or symptomatology of the disease; (2)
inhibiting the disease; for example, inhibiting a e, condition or disorder in an
individual who is experiencing or displaying the pathology or matology of the
disease, condition or disorder (i.e., arresting r development of the pathology
and/or symptomatology); and (3) ameliorating the disease; for example, ameliorating
a disease, condition or disorder in an individual who is experiencing or displaying the
pathology or symptomatology of the disease, condition or disorder (i.e., reversing the
ogy and/or symptomatology) such as sing the severity of disease.
Combination Therapies
The methods described herein can further comprise administering one or more
additional therapeutic agents. The one or more additional therapeutic agents can be
administered to a t simultaneously or sequentially.
In some embodiments, the method further comprises administering an
additional therapeutic agent selected from IMiDs, an anti-IL-6 agent, an anti—TNF-(x
agent, a hypomethylating agent, and a biologic response er (BRM).
Generally, a BRM is a substances made from living organisms to treat disease,
which may occur naturally in the body or may be made in the laboratory. Examples
of BRMs include IL-2, interferon, various types of colony-stimulating s (CSF,
, G—CSF), monoclonal antibodies such as abciximab, etanercept, infliximab,
rituximab, trasturzumab, and high dose ascorbate.
In some embodiments, the anti—TNF-(x agent is infliximab, and etanercept.
In some embodiments, the hypomethylating agent is a DNA methyltransferase
inhibitor. In some embodiments, the DNA transferase inhibitor is selected
from 5 azacytidine and decitabine.
Generally, IMiDs are as immunomodulatory agents. In some embodiments,
the IMiD is selected from thalidomide, lenalidomide, pomalidomide, 06, and
CC—100 15.
In some ments, the method further comprises administering an
onal therapeutic agent selected from hymocyte globulin, recombinant
human granulocyte -stimulating factor (G CSF), granulocyte—monocyte CSF
(GM-CSF), a erythropoiesis-stimulating agent (BSA), and cyclosporine.
In some embodiments, the method further comprises administering an
additional JAK inhibitor to the patient. In some embodiments, the additional JAK
inhibitor is tofacitinib or ruxolitinib.
One or more additional therapeutic agents may include chemotherapeutics,
anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr—Abl, Flt—3,
RAF and FAK kinase inhibitors such as, for e, those described in WO
2006/056399, which is incorporated herein by nce in its entirety, or other agents
can be used in combination with the compounds described herein.
Example herapeutics include proteosome inhibitors (e.g., bortezomib),
thalidomide, id, and DNA-damaging agents such as melphalan, doxorubicin,
cyclophosphamide, Vincristine, etoposide, carmustine, and the like.
Example steroids include coriticosteroids such as dexamethasone or
prednisone.
Example Bcr-Abl inhibitors include the compounds, and pharmaceutically
acceptable salts thereof, of the genera and species disclosed in US. Pat. No.
,521,184, WO 04/005281, and US. Ser. No. 60/578,491, all ofwhich are
incorporated herein by nce in their entirety.
Example suitable Flt-3 inhibitors include compounds, and their
pharmaceutically acceptable salts, as disclosed in WC 03/037347, WO 03/099771,
and WO 04/046120, all of which are incorporated herein by reference in their entirety.
e suitable RAF inhibitors include compounds, and their
pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444,
both of which are incorporated herein by reference in their entirety.
Example le FAK inhibitors include compounds, and their
ceutically acceptable salts, as disclosed in WC 04/080980, WO 04/056786,
WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402, all ofwhich
are incorporated herein by reference in their entirety.
In some embodiments, one or more of the compounds of the invention can be
used in combination with one or more other kinase inhibitors including imatinib,
particularly for treating patients resistant to imatinib or other kinase inhibitors.
In some embodiments, a suitable chemotherapeutical agent can be selected
from antimetabolite agents, topoisomerase 1 tors, platinum analogs, taxanes,
anthracyclines, and EGFR inhibitors, and combinations thereof.
In some embodiments, antimetabolite agents include capecitabine,
gemcitabine, and fluorouracil (5—FU).
In some embodiments, taxanes include axel, Abraxane® (paclitaxel
protein—bound particles for injectable suspension), and Taxotere® (docetaxel).
In some embodiments, um analogs e latin, cisplatin, and
carboplatin.
In some embodiments, topoisomerase 1 tors include irinotecan and
can.
In some embodiment, anthracyclines include doxorubicin or liposomal
formulations of doxorubicin.
In some embodiments, the chemotherapeutic is FOLFIRINOX (5-FU,
lecovorin, irinotecan and oxaliplatin). In some ments, the chemotherapeutic
agent is gemcitabine and Abraxane® (paclitaxel protein-bound particles for injectable
suspension).
In some embodiments, the additional therapeutic agent is melphalan,
melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade
(bortezomib). Further additional agents used in the treatment of multiple myeloma
include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. The agents can be combined
with the present compounds in a single or uous dosage form, or the agents can
be administered simultaneously or sequentially as separate dosage forms.
In some embodiments, a corticosteroid such as dexamethasone is administered
to a patient in combination with at least one JAKlselective inhibitor where the
dexamethasone is administered intermittently as opposed to continuously.
In some further embodiments, combinations of one or more JAKl ive
inhibitors with other therapeutic agents can be administered to a patient prior to,
during, and/or after a bone marrow transplant or stem cell transplant.
In some embodiments, the additional therapeutic agent is fluocinolone
acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcon).
In some embodiments, the additional therapeutic agent is cyclosporine
(Restasis®).
In some embodiments, the additional eutic agent is a corticosteroid. In
some embodiments, the corticosteroid is triamcinolone, dexamethasone, fluocinolone,
cortisone, prednisolone, or olone.
In some embodiments, the additional therapeutic agent is selected from
DehydrexTM s Labs), de (Opko), sodium hyaluronate d,
Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T)
(testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista),
gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine,
doxycycline (ALTY-0501, Alacrity), minocycline, iDestrinTM (NP50301, Nascent
Pharmaceuticals), cyclosporine A (Nova22007, Novagali), racycline
(Duramycin, MOLIl901, Lantibio), CF101 (2S,3S,4R,5R)—3,4—dihydroxy—5—[6—[(3—
iodophenyl)methylamino]purinyl]-N-methyl-oxolanecarbamyl, Can-Fite
Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis),
RX-10045 (synthetic resolvin analog, Resolvyx), DYN15 is Therapeutics),
rivoglitazone , Daiichi Sanko), TB4 eRx), OPH-Ol (Ophtalmis
Monaco), PCSlOl (Pericor Science), REV1—31 (Evolutec), Lacritin (Senju),
pide (Otsuka—Novartis), OT-551 a), PAI-2 (University of Pennsylvania
and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis),
loteprednol etabonate, rituximab, diquafosol tetrasodium (INS3 65, Inspire), KLS—
0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab,
mycophenolate sodium, cept (Embrel®), hydroxychloroquine, NGX267
(TorreyPines Therapeutics), actemra, gemcitabine, oxaliplatin, L-asparaginase, or
thalidomide.
In some ments, the additional therapeutic agent is an anti-angiogenic
agent, cholinergic agonist, TRP-l receptor modulator, a calcium channel r, a
mucin secretagogue, MUCl stimulant, a calcineurin inhibitor, a corticosteroid, a
P2Y2 receptor agonist, a muscarinic receptor t, an mTOR inhibitor, another
JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor,
and FAK kinase inhibitor such as, for example, those described in ,
which is incorporated herein by nce in its entirety. In some embodiments, the
additional therapeutic agent is a tetracycline derivative (e. g., minocycline or
doxycline). In some embodiments, the onal therapeutic agent binds to FKBPlZ.
In some embodiments, the additional therapeutic agent is an alkylating agent
or DNA cross-linking agent; an anti-metabolite/demethylating agent (e. g., 5-
flurouracil, capecitabine or azacitidine); an anti-hormone therapy (e. g., hormone
receptor antagonists, SERMs, or aromotase inhibitor); a mitotic inhibitor (e. g.
vincristine or paclitaxel); an topoisomerase (I or II) tor (e.g. mitoxantrone and
irinotecan); an apoptotic rs (e. g. ABT—73 7); a nucleic acid therapy (e. g.
antisense or RNAi); nuclear receptor ligands (e. g., agonists and/or antagonists: all-
trans retinoic acid or bexarotene); epigenetic ing agents such as histone
deacetylase inhibitors (e. g. vorinostat), hypomethylating agents (e.g. bine);
regulators of protein stability such as Hsp90 inhibitors, ubiquitin and/or ubiquitin like
conjugating or deconjugating molecules; or an EGFR inhibitor (erlotinib).
ceutical Formulations and Dosage Forms
When employed as pharmaceuticals, the JAKl selective inhibitors can be
administered in the form of pharmaceutical compositions. These compositions can be
prepared in a manner well known in the pharmaceutical art, and can be administered
by a variety of routes, depending upon whether local or systemic treatment is desired
and upon the area to be treated. Administration may be topical (including
transdermal, mal, ophthalmic and to mucous membranes including intranasal,
vaginal and rectal delivery), pulmonary (e.g., by tion or insufflation of powders
or aerosols, ing by nebulizer; intratracheal or intranasal), oral or parenteral.
Parenteral administration includes intravenous, intraarterial, subcutaneous,
intraperitoneal intramuscular or injection or infusion; or ranial, e. g., intrathecal
or intraventricular, stration. Parenteral administration can be in the form of a
single bolus dose, or may be, for example, by a continuous perfusion pump.
Pharmaceutical compositions and formulations for topical stration may include
transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays,
liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily
bases, thickeners and the like may be necessary or desirable.
This invention also includes pharmaceutical compositions which contain, as
the active ingredient, the JAKl selective inhibitor described , or a
pharmaceutically acceptable salt thereof, in combination with one or more
ceutically acceptable carriers (excipients). In some embodiments, the
composition is suitable for topical administration. In making the compositions, the
active ingredient is typically mixed with an excipient, diluted by an excipient or
enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or
other container. When the excipient serves as a diluent, it can be a solid, olid,
or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets,
cachets, elixirs, suspensions, ons, solutions, syrups, aerosols (as a solid or in a
liquid ), ointments containing, for example, up to 10% by weight of the active
compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions,
and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the
appropriate particle size prior to combining with the other ingredients. If the active
compound is substantially insoluble, it can be milled to a particle size of less than 200
mesh. If the active compound is substantially water soluble, the particle size can be
adjusted by milling to provide a substantially uniform distribution in the ation,
e. g. about 40 mesh.
The JAKl ive inhibitors may be milled using known milling ures
such as wet milling to obtain a particle size appropriate for tablet formation and for
other ation types. Finely divided articulate) preparations of the JAKl
selective inhibitors can be ed by processes known in the art, e. g., see
International App. No. .
Some examples of suitable excipients include lactose, dextrose, sucrose,
sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth,
n, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose,
water, syrup, and methyl cellulose. The formulations can additionally include:
ating agents such as talc, magnesium stearate, and mineral oil; wetting agents;
emulsifying and suspending agents; preserving agents such as methyl- and
propylhydroxy-benzoates; sweetening agents; and ng agents. The compositions
can be formulated so as to e quick, sustained or delayed release of the active
ingredient after administration to the patient by employing procedures known in the
art.
In some embodiments, the pharmaceutical composition ses silicif1ed
microcrystalline cellulose (SMCC) and at least one compound bed herein, or a
pharmaceutically acceptable salt thereof. In some embodiments, the fied
microcrystalline cellulose comprises about 98% microcrystalline cellulose and about
2% silicon e w/w.
In some embodiments, the composition is a sustained release composition
sing at least one JAKl selective inhibitor described herein, or a
pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable
r. In some embodiments, the composition comprises at least one JAKl selective
inhibitor described herein, or a pharmaceutically acceptable salt thereof, and at least
one component selected from microcrystalline cellulose, lactose monohydrate,
ypropyl methylcellulose, and polyethylene oxide. In some embodiments, the
composition ses at least one JAKl selective inhibitor described herein, or a
pharmaceutically able salt thereof, and microcrystalline cellulose, lactose
monohydrate, and hydroxypropyl methylcellulose. In some embodiments, the
composition comprises at least one JAKl selective inhibitor described herein, or a
pharmaceutically acceptable salt thereof, and rystalline cellulose, lactose
drate, and polyethylene oxide. In some embodiments, the composition further
comprises magnesium stearate or silicon dioxide. In some embodiments, the
microcrystalline cellulose is Avicel PHlOZTM. In some embodiments, the lactose
monohydrate is lo 316““. In some embodiments, the hydroxypropyl
methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M
PremierTM) and/or hydroxypropyl methylcellulose 2208 K100LV (e. g., Methocel
M). In some embodiments, the hylene oxide is polyethylene oxide
WSR 1105 (e.g., Polyox WSR 1105““).
In some embodiments, a wet granulation process is used to produce the
composition. In some embodiments, a dry ation process is used to produce the
composition.
The compositions can be formulated in a unit dosage form, each dosage
containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about
500 mg, of the active ingredient. In some embodiments, each dosage contains about
mg of the active ingredient. In some embodiments, each dosage contains about 50
mg of the active ingredient. In some embodiments, each dosage contains about 25 mg
of the active ingredient. The term "unit dosage forms" refers to physically discrete
units suitable as unitary dosages for human subjects and other mammals, each unit
containing a predetermined quantity of active material ated to e the
desired therapeutic effect, in association with a suitable pharmaceutical excipient.
In some embodiments, the compositions contain from about 2 mg to about 10
mg, or about 5 mg to about 50 mg of the active ient. One having ordinary skill
in the art will appreciate that this embodies compounds or compositions containing
about 2 mg to about 10 mg, 5 mg to about 10 mg, about 10 mg to about 15 mg, about
mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg,
about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45
mg, or about 45 mg to about 50 mg of the active ingredient.
In some ments, the compositions contain from about 50 mg to about
500 mg of the active ingredient. One having ordinary skill in the art will appreciate
that this embodies compounds or compositions containing about 50 mg to about 100
mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to
about 250 mg, about 250 mg to about 300 mg, about 350 mg to about 400 mg, or
about 450 mg to about 500 mg of the active ingredient.
In some embodiments, the compositions contain from about 500 mg to about
1,000 mg of the active ingredient. One having ordinary skill in the art will appreciate
that this embodies compounds or compositions containing about 500 mg to about 550
mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to
about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg, about
800 mg to about 850 mg, about 850 mg to about 900 mg, about 900 mg to about 950
mg, or about 950 mg to about 1,000 mg of the active ingredient.
The active compound may be effective over a wide dosage range and is
generally administered in a pharmaceutically effective amount. It will be tood,
however, that the amount of the compound actually administered will usually be
determined by a physician, according to the relevant circumstances, ing the
condition to be treated, the chosen route of administration, the actual compound
administered, the age, weight, and se of the individual patient, the severity of
the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active
ingredient is mixed with a pharmaceutical excipient to form a solid preformulation
composition containing a homogeneous mixture of a compound described herein, or a
pharmaceutically acceptable salt thereof When referring to these preformulation
compositions as homogeneous, the active ingredient is typically dispersed evenly
throughout the ition so that the composition can be readily subdivided into
equally effective unit dosage forms such as tablets, pills and capsules. This solid
preformulation is then subdivided into unit dosage forms of the type described above
containing from, for example, about 0.1 to about 1000 mg of the active ingredient of
the present ion.
The tablets or pills can be coated or otherwise compounded to provide a
dosage form ing the advantage of prolonged action. For example, the tablet or
pill can comprise an inner dosage and an outer dosage component, the latter being in
the form of an envelope over the former. The two ents can be separated by an
enteric layer which serves to resist disintegration in the stomach and permit the inner
component to pass intact into the duodenum or to be delayed in release. A variety of
materials can be used for such enteric layers or coatings, such materials including a
number of polymeric acids and mixtures of polymeric acids with such materials as
shellac, cetyl l, and ose acetate.
The liquid forms in which the compounds and compositions can be
incorporated for administration orally or by injection include aqueous ons,
suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with
edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as
elixirs and similar ceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions
in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and
powders. The liquid or solid compositions may contain suitable pharmaceutically
able excipients as described supra. In some embodiments, the itions are
stered by the oral or nasal respiratory route for local or systemic effect.
Compositions in can be zed by use of inert gases. zed solutions may be
breathed directly from the zing device or the nebulizing device can be attached
to a face masks tent, or intermittent positive pressure ing e. Solution,
suspension, or powder compositions can be administered orally or nasally from
devices which deliver the formulation in an appropriate manner.
Topical ations can contain one or more conventional carriers. In some
embodiments, ointments can contain water and one or more hydrophobic carriers
selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene
glycol, white Vaseline, and the like. Carrier compositions of creams can be based on
water in combination with glycerol and one or more other components, e.g.
glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can
be ated using isopropyl alcohol and water, suitably in combination with other
components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In
some embodiments, topical formulations contain at least about 0.1, at least about 0.25,
at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the
compound described , or a pharmaceutically acceptable salt thereof. The topical
formulations can be suitably packaged in tubes of, for example, 100 g which are
optionally associated with instructions for the treatment of the select indication, e. g.,
psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary
ing upon what is being administered, the purpose of the administration, such as
prophylaxis or therapy, the state of the patient, the manner of administration, and the
like. In therapeutic applications, itions can be administered to a patient already
suffering from a disease in an amount sufficient to cure or at least partially arrest the
ms of the disease and its complications. Effective doses will depend on the
e condition being treated as well as by the judgment of the attending clinician
depending upon factors such as the severity of the disease, the age, weight and general
condition of the patient, and the like.
The itions administered to a patient can be in the form of
pharmaceutical compositions described above. These compositions can be ized
by conventional sterilization techniques, or may be sterile flltered. Aqueous solutions
can be packaged for use as is, or lyophilized, the lyophilized preparation being
combined with a sterile aqueous carrier prior to administration. The pH of the
nd preparations typically will be between 3 and 11, more preferably from 5 to
9 and most preferably from 7 to 8. It will be understood that use of certain of the
foregoing excipients, carriers, or stabilizers will result in the formation of
pharmaceutical salts.
The therapeutic dosage of a JAKl selective inhibitor bed herein, or a
pharmaceutically acceptable salt thereof, can vary according to, for example, the
particular use for which the treatment is made, the manner of administration of the
compound, the health and ion of the t, and the judgment of the
prescribing physician. The proportion or concentration of a compound described
herein, or a ceutically acceptable salt thereof, in a pharmaceutical composition
can vary depending upon a number of factors including dosage, chemical
characteristics (e. g., hobicity), and the route of administration. For example,
the JAKl selective inhibitor can be ed in an aqueous physiological buffer
on containing about 0.1 to about 10% w/v of the compound for parenteral
administration. Some typical dose ranges are from about 1 ug/kg to about 1 g/kg of
body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg
to about 100 mg/kg of body weight per day. The dosage is likely to depend on such
variables as the type and extent of progression of the disease or disorder, the overall
health status of the particular patient, the relative biological efficacy of the compound
selected, formulation of the excipient, and its route of administration. Effective doses
can be extrapolated from dose—response curves d from in vitro or animal model
test systems.
The itions of the invention can further include one or more additional
pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory
nd, or immunosuppressant, examples of which are listed hereinabove.
Kits
The present invention also includes pharmaceutical kits useful, for example, in
the treatment or prevention of a myelodysplastic syndrome, which include one or
more containers containing a pharmaceutical ition comprising a
eutically effective amount of a compound described herein, or a
pharmaceutically acceptable salt thereof. Such kits can further include, if d, one
or more of various conventional pharmaceutical kit components, such as, for example,
containers with one or more pharmaceutically acceptable carriers, additional
ners, etc., as will be readily apparent to those skilled in the art. Instructions,
either as inserts or as labels, indicating quantities of the ents to be
administered, guidelines for administration, and/or guidelines for mixing the
components, can also be included in the kit.
EXAMPLES
The invention will be described in greater detail by way of ic examples.
The following examples are offered for illustrative purposes, and are not intended to
limit the invention in any manner. Those of skill in the art will readily recognize a
variety of non-critical parameters which can be changed or modified to yield
essentially the same results. The compounds of the Examples have been found to be
JAK inhibitors according to at least one assay described herein.
e 1. 3-[1-(6-chloropyridinyl)pyrrolidinyl][4-(7H-pyrrolo[2,3-
d]pyrimidinyl)—1H-pyrazol—l-yl]propanenitrile (two different enantiomers
isolated)
Step I. benzyl 3-{2-cyan0-I—[4-(7—{[2-(trimethylsilyl)eth0xy]methyl}-7H-
pyrr010[2, 3-61]pyrimidinyD-IH-pyrazol—I-yl]ethyl}pyrrolidine-I-carb0xylate
Benzyl 3-[2-cyanovinyl]pyrrolidinecarboxylate (4.3 g, 0.017 mol, mixture
ofE and Z isomers prepared as described in Ex.742) was dissolved
in acetonitrile (270 mL). 1,8-Diazabicyclo[5.4.0]undec—7—ene (5.02 mL, 0.0336 mol)
was added, followed by 4-(1H—pyrazolyl)—7— {[2—(trimethylsilyl)ethoxy]methyl}—
7H—pyrrolo[2,3—d]pyrimidine (5.6 g, 0.017 mol, prepared as described in WO
2007/070514, Ex.65). The e was stirred at RT overnight. The solvent was
removed by rotary evaporation, and the residue was redissolved in ethyl acetate. The
solution was washed successively with 1N HCl, water, saturated sodium bicarbonate,
and brine, dried over sodium sulfate and trated in vacuo. The product was
purified by flash column chromatography on silica gel, eluting with a gradient of 0-
100% ethyl e in hexanes to afford reomer 1 (first to elute) (3.5g, 36%) and
diastereomer 2 (second to elute) (2.5g, 25%). LCMS (M+H)+: 572.2.
Step 2. 3-pyrrolidinyl[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
0[2, 3-d]pyrimidinyl)-IH-pyrazol—I-yl]propanen itrile
Benzyl 3 -{2-cyano[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-
o [2,3 -d]pyrimidinyl)—1H-pyrazolyl]ethyl}pyrrolidinecarboxylate (3 .5
g, 6.1 mmol) (diastereomer 1 from e 1, Step 1) was dissolved in 100 mL
methanol, and a catalytic amount of 10% Pd-C was added. The mixture was shaken
under 50 psi of hydrogen for 24 h. The mixture was then filtered and the solvent
removed in vacuo. The product was used without further purification. LCMS (M+H)+:
438.2.
Step 3. 3-[1-(6—chloropyridinyl)pyrrolidinyZ][4-(7-{[2-
(trimethylsilybethoxflmethyl}- 7H-pyrr010[2, 3-d]pyrimidinyl)-IH-pyrazol—I—
yUpropanenitrile
A mixture of 3-pyrrolidin-3 -yl[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazolyl]propanenitrile (150 mg, 0.27 mmol)
and 2,6-dichloropyridine (48.7 mg, 0.329 mmol) in NMP (1.6 mL) and N,N—
diisopropylethylamine (96 microL, 0.55 mmol) was heated to 135°C for 20 min in the
microwave. Purification by flash column chromatography on silica gel, eluting with a
gradient from 0-80% ethyl acetate in hexanes, afforded the title product (28 mg,
18%). 1H NMR (400 MHz, CDC13): 8 8.85 (s, 1H), 8.36 (s, 1H), 8.36 (s, 1H), 7.41
(d, 1H), 7.37 (dd, 1H), 6.79 (d, 1H), 6.57 (d, 1H), 6.22 (d, 1H), 5.68 (s, 2H), 4.45 (dt,
1H), 3.91 (dd, 1H), 3.57—3.46 (m, 3H), 3.39—3.29 (m, 2H), 3.24 (dd, 1H), .01
(m, 1H), 3.01 (dd, 1H), 1.98—1.88 (m, 1H), .69 (m, 1H), .88 (m, 2H), —
0.06 (s, 9H); LCMS (M+H)+: 549.1.
This c product was separated into its enantiomers by chiral HPLC
(Chiral Technologies Chiralcel OJ-H, 5p, 30 x 250mm, 45% EtOH/Hexanes, 20
mL/min) to afford enantiomer 1 (first to elute, retention time 40.7 min) and
enantiomer 2 (second to elute, retention time 51.6 min), which were deprotected
separately in Steps 4a/4b.
Step 4a. 3-[1-(6—ch[0ropyridin-Z-ybpyrrolidinyl][4-(7H—pyrr010[2,3-
d]pyrimidinyl)-IH—pyrazol—I—yUpropanenitrile (enantiomer I)
3 -[1-(6-Chloropyridinyl)pyrrolidinyl]—3 -[4-(7- {[2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazol
yl]propanenitrile (enantiomer 1 from Step 3) was d in a solution containing 1:1
TFA/DCM (2 mL) for 2 h, and then concentrated. The residue was dissolved in 1 mL
MeOH, and 0.2 mL EDA was added. Purification Via preparative-HPLC/MS (C18
column g with a gradient HzO containing 0.15% NH4OH) afforded
product. 1H NMR (400 MHz, CDC13): 8 9.44 (br s, 1H), 8.84 (s, 1H), 8.37 (s, 2H),
7.39 (dd, 1H), 7.38 (dd, 1H), 6.79 (dd, 1H), 6.58 (d, 1H), 6.22 (d, 1H), 4.46 (dt, 1H),
3.92 (dd, 1H), 3.55—3.48 (m, 1H), 3.39—3.31 (m, 2H), 3.25 (dd, 1H), 3.13—3.02 (m,
1H), 3.02 (dd, 1H), 2.00—1.88 (m, 1H), 1.84—1.71 (m, 1H); LCMS (M+H)+: 419.1.
Step 4]). 3-[1-(6—ch[0ropyridin-Z-ybpyrrolidinyl][4-(7H—pyrr010[2,3-
d]pyrimidinyl)-IH—pyrazol—I-yl]pr0panenitrile(enanti0mer 2)
Performed as in Step 4a, using omer 2 from Step 3: 1H NMR (400
MHz, CDC13): 8 9.59 (br s, 1H), 8.84 (s, 1H), 8.37 (s, 2H), 7.40 (dd, 1H), 7.38 (dd,
1H), 6.79 (dd, 1H), 6.58 (d, 1H), 6.22 (d, 1H), 4.46 (dt, 1H), 3.92 (dd, 1H), 3.55—3.48
(m, 1H), 3.39—3.31 (m, 2H), 3.25 (dd, 1H), 3.14—3.02 (m, 1H), 3.02 (dd, 1H), 1.99—
1.90 (m, 1H), 1.83—1.72 (m, 1H); LCMS (M+H)+: 419.1.
Example 2. 3-(1-[1,3]0xazolo[5,4—b]pyridin-Z-ylpyrrolidinyl)—3-[4-(7H-pyrrolo[2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl]propanenitrile (one enantiomer isolated)
Step 1. 3-(1-[1,3]0xazol0[5,4-b]pyridinylpyrr0Zidz’nyl)[4-(7-{[2-
(trimethylsilyDethoxy]methyZ}-7H-pyrr0l0[2,3-d]pyrimidinyZ)-1H—pyrazoZ-I-
yUpropanenitrile
Oxazolo[5,4-b]pyridine-2(1H)—thione (1.17 g, 7.68 mmol, prepared as in Example 33
ofUS 298334, Step 4) and 3-pyrrolidiny1[4-(7-{[2-
(trimethylsi1y1)ethoxy]methy1} -7H-pyrrolo [2 ,3 -d]pyrimidiny1)— 1 H-pyrazol
y1]propanenitrile (2.80 g, 6.40 mmol from Example 15, Step 3) in 1,4-dioxane (30 mL) was
heated to 70 °C for 2 h. The solvent was removed in vacuo. The crude t was
reconstituted in ethanol (40 mL) and treated with silver nitrate (3 g, 15 mmol) and aqueous
ammonium hydroxide (6 mL) nwise over the course of 20 h. Into the reaction was
added water, 1N NaOH and brine. Insoluble material was removed by filtration. The layers of
the filtrate were separated. The aqueous portion was extracted with three portions of ethyl
acetate. The extracts were dried over sodium sulfate, decanted and trated. The crude
product was purified by flash column chromatography on silica gel, eluting with 10%
MeOH/DCM to afford the product as an off-white foam (2.84 g, 80%). 1H NMR (300 MHz,
CDCl3)2 8 8.83 (s, 1H), 8.37 (s, 1H), 8.36 (s, 1H), 7.92 (dd, 1H), 7.57 (dd, 1H), 7.40 (d,
1H), 7.13 (dd, 1H), 6.78 (d, 1H), 5.67 (s, 2H), 4.52 (dt, 1H), 4.05 (dd, 1H), 3.82 (ddd, 1H),
3.67-3.44 (m, 4H), 3.25 (dd, 1H), 3.24-3.09 (m, 1H), 2.98 (dd, 1H), 2.06-1.74 (m, 2H), 0.97-
0.88 (m, 2H), -0.06 (s, 9H); LCMS (M+H)+: 556.1.
Step 2. 3-(1-[1,3]0xazolo[5,4-b]pyridinylpyrr0ZidinyD[4-(7H-pyrr0l0[2,3-
d]pyrimidiny[)-IH-pyrazol-I-yUpropanenitrile
3 -(1-[1,3]Oxazolo[5 yridin-2 -ylpyrrolidinyl) [4-(7- { [2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2 ,3 -d]pyrimidinyl)-1H-pyrazol
panenitrile (5.35 g, 9.63 mmol, ed by the method of Step 1) was stirred in a 2:1
mixture ofDCM and TFA (60 mL) for 6 h. The solvents were removed by rotary evaporation.
The crude residue was dissolved in ol (50 mL) containing EDA (5.15 mL, 77.0 mmol)
and was stirred overnight. After removal of solvent, the product was purified by flash column
chromatography on silica gel, g with a gradient from 0-15% MeOH/DCM (3.59 g,
88%). 1H NMR (300 MHz, CDC13)2 5 8.72 (s, 1H), 8.40 (s, 1H), 8.34 (s, 1H), 7.89 (dd,
1H), 7.54 (dd, 1H), 7.36 (d, 1H), 7.12 (dd, 1H), 6.75 (d, 1H), 4.56 (dt, 1H), 4.01 (dd, 1H),
3.80 (ddd, 1H), 3.60 (ddd, 1H), 3.48 (dd, 1H), 3.26 (dd, 1H), 3.21-3.06 (m, 1H), 3.02 (dd,
1H), 2.03-1.76 (m, 2H); LCMS (M+H)+: 426.1.
Example 3. 4-[(4-{3-cyano[4-(7H-pyrrolo[2,3-d]pyrimidin-4—yl)—1H-pyrazol—1-
yl]propyl}piperazinyl)carbonyl]flu0r0benzonitrile trifluoroacetate salt
(single enantiomer isolated)
o /—\
N\ [NLCN
F N-N
NC ° 2.4 TFA
”m \ \
N’ H
Step I. (R)- and (S)- tert—bulyl 4-{3-cyan0[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrr010[2, 3-d]pyrimidin-4—yD-IH—pyrazol—I-yl]propyl}piperazine-I-carb0xylate
1,8—Diazabicyclo[5.4.0]undec—7—ene (5.5 mL, 0.037 mol) was added to a
solution of (E)— and (Z)—tert-buty1 4-(3-cyanoa11y1)piperazinecarboxy1ate (11.1 g,
0.0441 mol, ed as in Example 1 of US 2011/0059951, Steps 1-2) and 4-(1H-
pyrazoly1) {[2-(trimethy1si1y1)ethoxy]methyl} -7H-pyrrolo[2,3 -d]pyrimidine
(11.6 g, 0.0368 mol, prepared as described in W02007/070514, Example 65) in
acetonitrile (70 mL). The e was stirred at 50 °C for 15 hours. Solvents were
removed in vacuo. The residue was dissolved in ethyl acetate, washed with water (3
times), brine (once), dried over sodium sulfate and trated. Flash column
chromatography, followed by ative HPLC-MS (eluting with a gradient of
MeCN/HzO containing 0.15% NH4OH) afforded product as a white foam (8.20 g,
39%).
Chiral HPLC was used to separate the racemic mixture into single enantiomers
(Phenomenex Lux-Cellulose-2, 21.2 x 250 mm, 5 pm, eluting with
%EtOH/70%Hexanes, at in). Peak 1 (first to elute): 4.0 g and peak 2
(second to elute): 4.0 g. 1H NMR Peak 1 (400 MHz, CDCl3): 5 8.84 (s, 1H), 8.33 (s,
1H), 8.31 (s, 1H), 7.40 (d, 1H), 6.79 (d, 1H), 5.68 (s, 2H), 4.70—4.62 (m, 1H), 3.58—
3.51 (m, 2H), 3.44—3.35 (br m, 4H), 3.16 (dd, 1H), 3.10 (dd, 1H), 2.99 (dd, 1H), 2.89
(dd, 1H), 2.50—2.40 (br m, 4H), 1.44 (s, 9H), 0.95—0.89 (m, 2H), —0.06 (s, 9H); LCMS
(M+H)+: 567.3. 1H NMR Peak 2 (400 MHz, CDCl3): 5 8.84 (s, 1H), 8.32 (s, 1H),
8.31 (s, 1H), 7.40 (d, 1H), 6.79 (d, 1H), 5.68 (s, 2H), 4.70—4.62 (m, 1H), 3.58—3.51 (m,
2H), 3.45—3.34 (br m, 4H), 3.16 (dd, 1H), 3.10 (dd, 1H), 2.99 (dd, 1H), 2.90 (dd, 1H),
2.50—2.40 (br m, 4H), 1.44 (s, 9H), 0.95—0.89 (m, 2H), —0.06 (s, 9H); LCMS (M+H)+:
567.3.
Step 2. razin-I-yl[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr0l0[2,3-
d]pyrimidinyl)-IH—pyrazol—I-yUbutanenitrile hydrochloride salt
tert-Butyl 4- {3-cyano[4-(7- {[2-(trimethylsilyl)ethoxy]methyl} -7H-
pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -yl]propyl}piperazine- l -carboxylate (4.0
g, 7.0 mmol; Peak 2 from Step 1) was dissolved in l,4-dioxane (40 mL), and 4.0 M of
HCl in dioxane (25 mL, 100 mmol) was added. The mixture was stirred at room
temperature for 80 min. Solvent was removed in vacuo to afford the product as the
hydrochloride salt. LCMS : 467.3.
Step 3. {3-cyan0[4-(7H—pyrr0l0[2,3-d]pyrimidinyl)-IH—pyrazol—I—
yl]pr0pyl}piperazin-I-yl)carbonyl}3-flu0r0benzonitrile trifluoroacetate salt
A mixture of 4-cyanofluorobenzoic acid (138 mg, 0.836 mmol, Alfa
Aesar), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol- l -yl)uronium
hexafluorophosphate (254 mg, 0.669 mmol) and triethylamine (0.466 mL, 3.34 mmol)
in THF (10.0 mL) was stirred at room ature for 15 minutes. 4-Piperazinyl
[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidinyl)-1H-
l—1-yl]butanenitrile hydrochloride (0.33 g, 0.56 mmol; from Step 2) was added.
The reaction was stirred at room temperature for one hour. The reaction was diluted
with ethyl acetate and water. The layers were separated and the organic layer was
washed successively with water, 0.1N NaOH and brine, dried over sodium e and
concentrated. The residue was dissolved in a 2:1 mixture of DCM:TFA, stirred for 3
hours, concentrated, then in a mixture of 8 mL methanol to which 0.8 mL of
ethylenediamine was added. After stirring for one hour, the product was purified Via
HPLC—MS, eluting with a nt of MeCN and H20 containing 0.2% TFA. Eluent
frozen and lyophilized to afford a white powder (200 mg, 47%). 1H NMR (400 MHz,
d6—dmso): 5 12.64 (br s, 1H), 8.97 (s, 1H), 8.83 (s, 1H), 8.51 (s, 1H), 7.99 (dd, 1H),
7.82—7.76 (m, 2H), 7.61 (t, 1H), 7.15—7.11 (m, 1H), 5.13 (br m, 1H), .37 (br,
12H); 19F NMR (400 MHz, d6—dmso): 5 —74.97 (s, 7.2 F), 9 (br s, 1F); LCMS
(M+H)+: 484.2.
Example 4. 4-[(4—{3-cyano[3-(7H-pyrrolo[2,3-d]pyrimidin-4—yl)—1H-pyrrol
yl]propy1}piperazinyl)carbonyl]flu0r0benzonitrile trifluoroacetate salt
(single enantiomer isolated)
(jug,
/ 3.3 TFA
NC\/
Step I. tert—bulyl 4-{3-cyan0[3-(7-{[2-(trimethylsilyl)eth0xy]methyl}-7H-
pyrr010[2, 3-d]pyrimidinyl)-IH—pyrrol—I-yl]propyl}piperazine-I-carb0xylate
To a mixture of (E)- and (Z)-tert-butyl 4-(3-cyanoallyl)piperazine
carboxylate (4.0 g, 0.016 mol; prepared as in Example 1 of US 2011/0059951, Steps
1-2) and 4-(1H-pyrrol-3 -yl) {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidine (4.2 g, 0.013 mol, prepared as in WO2009/114512, Example 82) in N,N-
Dimethylformamide (25 mL) was added ium carbonate (5.540 g, 0.0401 mol).
The mixture was d at 60 0C for 17 hours. Additional (E)— and (Z)-tert-butyl 4-(3-
cyanoallyl)piperazine—1—carboxylate (4.0 g, 0.016 mol) was added and the reaction
was stirred at 60 0C for 24 hours. A further portion of (E)- and (Z)-tert-butyl 4-(3-
cyanoallyl)piperazinecarboxylate (4.0 g, 0.016 mol) was added. After 3 nights of
g, most of the starting material had been converted to desired product as
determined by LCMS. The mixture was then filtered, diluted with EtOAc, washed
with water (3 , brine (once), dried over sodium sulfate, decanted and
concentrated. Purification via preparative HPLC-MS (eluting with a gradient of
MeCN/HzO containing 0.15% NH4OH) afforded a brown foam (4.20 g, 55%). 1H
NMR (300 MHz, CDCl3): 5 8.81 (s, 1H), 7.66 (t, 1H), 7.34 (d, 1H), 6.97 (dd, 1H),
6.89 (t, 1H), 6.84 (d, 1H), 5.66 (s, 2H), 4.47—4.36 (m, 1H), 3.57—3.50 (m, 2H), 3.45—
3.37 (m, 4H), 3.06 (dd, 1H), 3.00—2.90 (m, 2H), 2.83 (dd, 1H), 2.57—2.35 (m, 4H),
1.45 (s, 9H), .86 (m, 2H), —0.06 (s, 9H); LCMS (M+H)+: 566.3.
Chiral HPLC was used to separate the racemate into single enantiomers
(Chiral logies ChiralPAK IA 20x250mm, 5pm, mobile phase
%EtOH/70%hexanes, flow rate 12mL/min). Peak 1 (first enantiomer to elute), 1.8
g; Peak 2 (second enantiomer to elute): 1.9 g.
Step 2. 4-piperazin-I-yl—3-[3-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2,3-
d]pyrimidin-4—yl)-IH—pyrrol—I—yUbutanenitrile hydrochloride salt
To a solution of utyl 4-{3-cyano[3-(7-{[2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)— 1 ol
yl]propyl}piperazinecarboxylate (1.9 g, 0.0034 mol; peak 2 of Step 1) in 1,4-
dioxane (20 mL) was added 4.0 M of HCl in p-dioxane (12 mL, 48 mmol). The
mixture was stirred at room temperature for 80 minutes. Solvent was removed in
vacuo, to afford product as a light yellow solid (1.90 g, 100%). LCMS (M+H)+:
466.3.
Step 3. 4-[(4-{3-cyan0[3-(7H—pyrr010[2,3-d]pyrimidinyl)-IH-pyrrol—I—
yUpropyl}piperazin-I-yl)carbonyU—S-fluombenzonitrile trifluoroacetate salt
A mixture of 4-cyanofluorobenzoic acid (44 mg, 0.26 mmol, Alfa Aesar),
N,N,N',N'-Tetramethyl-O-(7-azabenzotriazolyl)uronium Hexafluorophosphate (93
mg, 0.24 mmol) and triethylamine (171 uL, 1.22 mmol) in THF (2.4 mL) was stirred
at room temperature for 15 minutes. 4-Piperazinyl[3-(7-{[2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrrol
yl]butanenitrile hydrochloride salt (110 mg, 0.20 mmol; from Step 2) was added. The
reaction was stirred for 2 hours. Ethyl e and water were added. The layers were
separated and the organic layer was washed successively with water, 1N NaOH and
brine, dried over sodium sulfate and trated. The residue was dissolved first in a
1:1 mixture of DCM:TFA for 1 hour, was concentrated, then was stirred in ol
(2 mL) containing ethylenediamine (0.2 mL) for one hour. Purification via preparative
HPLC—MS (eluting with a gradient of MeCN/HzO containing 0.1% TFA afforded
product as the 3.3xTFA salt (84 mg, 48%). 1H NMR (300 MHz, d6—dmso): 5 13.22
(br s, 1H), 8.90 (s, 1H), 8.38 (s, 1H), 8.00 (dd, 1H), 7.97—7.93 (m, 1H), 7.80 (dd, 1H),
7.61 (t, 1H), 7.35 (s, 2H), 7.18—7.13 (m, 1H), 5.00—4.80 (m, 1H), .49 (br m, 2H),
3.35—2.33 (m, 10H); 19F NMR (300 MHz, o): 5 —74.82 (s, 10F), —114.53 (s, 1F);
LCMS (M+H)+: 483.2.
Example 5. {1-{1-[3-Fluoro(trifluoromethyl)isonic0tin0yl]piperidin-4—yl}[4—
(7H-pyrrolo [2,3-d]pyrimidin-4—yl)—1H-pyrazol—l-yl]azetidinyl}acetonitrile
O \
/=2 /
2 I2
Step A: tert—Bulyl 3-Ox0azetidine-I—carboxylate
To a mixture of tert—butyl 3—hydroxyazetidine—1—carboxy1ate (10.0 g, 57.7
mmol), dimethyl sulfoxide (24.0 mL, 338 mmol), triethylamine (40 mL, 300 mmol)
and methylene chloride (2.0 mL) was added sulfur trioxide-pyridine complex (40 g,
200 mmol) portionwise at 0 0C. The mixture was stirred for 3 hours, quenched with
brine, and ted with methylene chloride. The ed ts were dried over
anhydrous NazSO4, filtered, and concentrated under reduced re. The e
was purified by silica gel column (0-6% ethyl acetate ) in hexanes) to give
tert—butyl 3—oxoazetidine—1—carboxy1ate (5.1 g, 52% yield).
Step B: tert—Bulyl 3-(Cyanomethylene)azetidine-I—carboxylate
An oven-dried 1 L 4-neck round bottom flask fitted with stir bar, septa,
nitrogen inlet, 250 ml addition funnel and thermocouple was charged with sodium
hydride (5.6 g, 0.14 mol) and tetrahydrofuran (THF) (140 mL) under a nitrogen
here. The mixture was chilled to 3 0C, and then charged with diethyl
cyanomethylphosphonate (22.4 mL, 0.138 mol) dropwise Via a syringe over 20
minutes. The solution became a light yellow slurry. The reaction was then stirred for
75 minutes while warming to 18.2 0C. A solution of tert—butyl 3-oxoazetidine
carboxylate (20 g, 0.1 mol) in tetrahydrofuran (280 mL) was prepared in an oven-
dried round bottom, charged to the addition funnel Via canula, then added to the
reaction mixture dropwise over 25 minutes. The reaction on became red in color.
The on was allowed to stir overnight. The reaction was checked after 24 hours
by TLC (70% hexane/EtOAc) and found to be complete. The reaction was diluted
with 200 mL of 20% brine and 250 mL of EtOAc. The solution was partitioned and
the aqueous phase was extracted with 250 mL of EtOAc.The combined organic phase
was dried over MgSO4 and filtered, evaporated under reduced re, and purified
by flash chromatography ( 0% to 20% EtOAc/hexanes, 150 g flash column) to give
the desired product, tert—butyl 3—(cyanomethylene)azetidine—1—carboxy1ate (15 g,
66.1% yield).
Step C: 4—Chlor0{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2,3-d]pyrimidine
To a suspension of sodium hydride (36.141 g, 903.62 mmol) in N,N—
ylacetamide (118 mL) at -5 0C (ice/salt bath) was added a dark solution of 4—
chloropyrrolo[2,3—d]pyrimidine (119.37 g, 777.30 mmol) in N,N—dimethylacetamide
(237 mL) slowly. The flask and addition funnel were rinsed with N,N—
dimethylacetamide (30 mL). A large amount of gas was evolved immediately. The
e became a slightly cloudy orange mixture. The mixture was stirred at 0 0C for
60 min to give a light brown turbid mixture. To the mixture was slowly added [2—
(trimethylsilyl)ethoxy]methyl chloride (152.40 g, 914.11 mmol) and the reaction was
stirred at 0 0C for 1 h. The reaction was quenched by addition of 12 mL of H20
slowly. More water (120 mL) was added followed by methyl tert—butyl ether (MTBE)
(120 mL). The e was stirred for 10 min. The organic layer was separated. The
aqueous layer was extracted with another portion of MTBE (120 mL). The organic
extracts were combined, washed with brine (120 mL X 2) and concentrated under
reduced pressure to give the crude product ro—7— {[2—
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine as a dark oil. Yield:
85.07 g (97%); LC—MS: 284.1 (M+H)+. It was carried to the next reaction without
purification.
Step D: Pyrazol—4—yl)-7—{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2, 3-
d]pyrimidine
A 1000 mL round bottom flask was charged with 4-chloro {[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (10.00 g, 35.23 mmol),
1-butanol (25 .0 mL), 1 -(1 -ethoxyethyl)(4,4,5,5-tetramethyl- 1,3 ,2-dioxaborolan
yl)-1H-pyrazole (15.66 g, 52.85 mmol), water (25.0 mL) and potassium carbonate
(12.17 g, 88.08 mmol). This solution was degased 4 times, filling with nitrogen each
time. To the solution was added tetrakis(triphenylphosphine)palladium(0) (4.071 g,
3.523 mmol). The solution was degased 4 times, filling with nitrogen each time. The
mixture was stirred overnight at 100 0C. After being cooled to room temperature, the
mixture was filtered through a bed of celite and the celite was rinsed with ethyl
acetate (42 mL). The e was combined, and the c layer was separated. The
aqueous layer was extracted with ethyl acetate. The organic extracts were combined
and concentrated under vacuum with a bath temerature of 30-70 0C to give the final
compound pyrazolyl)—7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
midine. Yield: 78%. LC—MS: 316.2 (M+H)+.
Step E: tert—Bulyl 3-(Cyan0methyD[4-(7-{[2-(trimethylsilyDethoxy]methyl}-7H-
pyrr010[2, 3-d]pyrimidinyD-IH-pyrazol—I-yl]azetidine-I-carb0xylate
A 2 L round bottom flask fitted with overhead stirring, septa and en inlet
was charged with tert—butyl nomethylene)azetidinecarboxylate (9.17 g,
0.0472 mol), 4-(1H-pyrazolyl){[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3-d]pyrimidine (14.9 g, 0.0472 mol) and acetonitrile (300 mL). The
resulting solution was heterogeneous. To the on was added 1,8—
diazabicyclo[5.4.0]undec—7—ene (8.48 mL, 0.0567 mol) portionwise via syringe over 3
min at room temperature. The solution slowly became homogeneous and yellow in
color. The on was allowed to stir at room ature for 3 h. The reaction was
complete by HPLC and LC/MS and was concentrated by rotary evaporation to
remove acetonitrile (~150 mL). EtOAc (100 mL) was added followed by 100 ml of
% brine. The two phases were partitioned. The aqueous phase was extracted with
150 mL of EtOAC. The combine organic phases were dried over MgSO4, filtered and
concentrated to yield an orange oil. Purification by flash chromatography (150 grams
silica, 60% EtOAc/hexanes, loaded with CHzClz) d the title compound tert—
butyl 3 -(cyanomethyl)-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo[2,3 -
d]pyrimidinyl)-1H-pyrazolyl]azetidinecarboxylate as a yellow oil (21.1 g,
88% yield). LC—MS: [M+H]+ = 510.3.
Step F.‘ {3-[4-(7-{[2-(Trimethylsilybethoxy]methyl}-7H-pyrr010[2, 3-d]pyrimidin
yD-IH-pyrazol—I-yUazetidin-S-yl}acet0nitrile dihydrochloride
To a solution of tert—butyl 3—(cyanomethy1)—3—[4—(7— {[2—
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)- 1 H-pyrazol
yl]azetidine—1-carboxylate (2 g, 3.9 mmol) in 10 mL of THF was added 10 mL of 4 N
HCl in dioxane. The solution was stirred at room temperature for 1 hour and
concentrated in vacuo to provide 1.9 g (99%) of the title compound as a white powder
solid, which was used for the next reaction without purification. LC—MS: [M+H]+ =
410.3.
Step G: tert—Bulyl 4-{3-(Cyan0methyD[4-(7-{[2-(trimethylsilyl) ethoxy]methyl}-
7H-pyrr010[2, 3-d]pyrimidinyl)-IH—pyrazol—I—yUazetidin-I—yl}piperidine-I—
carboxylate
Into the on of {3-[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -yl] azetidin-3 -yl} acetonitrile
dihydrochloride (2.6 g, 6.3 mmol), tert—butyl 4—oxo-l-piperidinecarboxylate (1.3 g,
6.3 mmol) in THF (30 mL) were added N,N—diisopropylethylamine (4.4 mL, 25
mmol) and sodium triacetoxyborohydride (2.2 g, 10 mmol). The mixture was stirred
at room temperature overnight. After adding 20 mL of brine, the solution was
extracted with EtOAc. The extract was dried over anhydrous NazSO4 and
concentrated. The residue was purified by combiflash column eluting with 30—80 %
EtOAc in hexanes to give the d product, tert—butyl 4— {3—(cyanomethyl)—3—[4—(7—
{[2-(trimethylsilyl) ethoxy]methyl} rrolo[2,3 -d]pyrimidinyl)- lH-pyrazol- l -
yl]azetidin-l-yl}piperidine-l-carboxylate. Yield: 3.2 g (86%); LC—MS: =
593.3.
Step H: {I-Pzperidinyl—3-[4-(7—{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2,3-
d]pyrimidin-4—yD-IH—pyrazol—I-yl]azetidin-S-yl}acet0nitrile trihydrochloride
To a solution of tert—butyl 4— anomethyl)—3—[4—(7— {[2-(trimethylsilyl)
ethoxy]methyl} -7H-pyrrolo[2,3 -d]pyrimidinyl)- l zol- l -yl] azetidin- l -
yl}piperidine-l-carboxylate (3.2 g, 5.4 mmol) in 10 mL of THF was added 10 mL of
4 N HCl in dioxane. The reaction mixture was d at room temperature for 2 hours.
Removing solvents under reduced pressure yielded 3.25 g (100%) of {l—piperidin—4—
yl-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)- lH-
pyrazol-l-yl]azetidinyl}acetonitrile trihydrochloride as a white powder solid,
which was used directly in the next reaction. LC—MS: [M+H]+ = 493.3. 1H NMR (400
MHz, DMSO—ds): 5 9.42 (s 1H), 9.21 (s, 1H), 8.89 (s, 1H), 8.69 (s, 1H), 7.97 (s, 1H),
7.39 (d, 1H), 5.68 (s, 2H), 4.96 (d, 2H), 4.56 (m, 2H), 4.02—3.63 (m, 2H), 3.55 (s, 2H),
3.53 (t, 2H), 3.49—3.31 (3, 3H), 2.81 (m, 2H), 2.12 (d, 2H), 1.79 (m, 2H), 0.83 (t, 2H),
—0.10 (s, 9H).
Step I: {I-{I—[3-Flu0r0(trifluoromethyl)isonicotinoyUpmeridin-él-yl}[4-(7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2,3-d]pyrimidinyl)-IH—pyrazol—I—
yl]azetidinyl}acet0nitrile
A mixture of {1-piperidinyl[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-
7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazolyl]azetidin-3 -yl} itrile
trihydrochloride (1.22 g, 2.03 mmol), 3-fluoro(trifluoromethyl)isonicotinic acid
(460 mg, 2.2 mmol), benzotriazol-l-yloxytris(dimethylamino)phosphonium
hexafluorophosphate (1.07 g, 2.42 mmol), and triethylamine (2.0 mL, 14 mmol) in
dimethylformamide (DMF) (20.0 mL) was stirred at room temperature overnight.
LS—MS showed the reaction was te. EtOAc (60 mL) and ted NaHCO3
aqueous solution (60 mL) were added to the on mixture. After stirring at room
ature for 10 minutes, the organic phase was seperated and the aqueous layer
was extracted with EtOAc three times. The combined organic phase was washed with
brine, dried over anhydrous NazSO4, filtered and evaporated under reduced pressure.
Purification by flash chromatography provided the desired product {1—{1—[3—fluoro—2—
(trifluoromethyl)isonicotinoyl]piperidinyl} [4-(7- {[2-
thylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazol
yl]azetidinyl}acetonitrile. LC—MS: 684.3 (M+H)+.
Step J: {I-{I-[3-FZu0r0(trifluoromethyl)isonicotin0y]]piperidinyl}[4-(7H—
pyrr010[2,3-d]pyrimidinyl)-IH—pyrazol—I-yl]azetidinyl}acet0nitrile
Into a solution of {1-{1-[3-fluoro(trifluoromethyl)isonicotinoyl]piperidin-
4-yl} -3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)-
1H-pyrazolyl]azetidinyl}acetonitrile (56 mg, 0.1 mmol) in methylene chloride
(1.5 mL) was added trifluoroacetic acid (1.5 mL). The mixture was stirred at room
temperature for 2 hours. After removing the solvents in , the residue was
dissolved in a methanol solution containing 20% ethylenediamine. After being d
at room temperature for 1 hour, the solution was purified by HPLC (method B) to
give the title compound. LC—MS: 554.3 (M+H)+; 1H NMR (400 MHz, CDCl3): 9.71
(s, 1H), 8.82 (s, 1H), 8.55 (d, J=4.6 Hz, 1H), 8.39 (s, 1H), 8.30 (s, 1H), 7.52 (t, J=4.6
Hz, 1H), 7.39 (dd, Ji=3.4 Hz, Jz=1.5 Hz, 1H), 6.77 (dd, Ji=3.6 Hz, Jz=0.7 Hz, 1H),
4.18 (m, 1H), 3.75 (m, 2H), 3.63 (dd, Ji=7.8 Hz, Jz=3.7 Hz, 2H), 3.45 (m, 2H), 3.38
(s, 2H), 3.11 (m, 1H), 2.57 (m, 1H), 1.72 (m, 1H), 1.60 (m, 1H), 1.48 (m, 1H), 1.40
(m, 1H).
Example 6. 4-{3-(Cyanomethyl)—3-[4-(7H-pyrrolo [2,3-d]pyrimidinyl)—1H-
pyrazol—l-yl]azetidin-l-yl}-N-[4-flu0r0(triflu0r0methyl)phenyl]piperidine—l-
carboxamide
Step A: 4-{3-(Cyan0methyD[4-(7-{[2-(trimethylsilybeth0xy]methyl}-7H-
pyrr010[2,3-d]pyrimidinyl)-IH-pyrazol—I—yUazetidin-I—yl}-N-[4-flu0r0
(trzj’luoromethybphenyUpiperidine-I—carboxamide
To a solution of {1-piperidiny1—3-[4-(7- { [2-(trimethy1sily1)ethoxy]methy1} -
7H-pyrrolo [2,3 -d]pyrimidiny1)-1H-pyrazoly1]azetidin-3 -y1} acetonitrile
trihydrochloride (500 mg, 1 mmol) in tetrahydrofuran (30 mL) were added
triethylamine (0.29 g, 2.8 mmol) and 4-fluoroisocyanato
(trifluoromethy1)benzene (190 mg, 0.95 mmol). The e was stirred at room
temperature for 1 hour. The solvent was removed under reduced pressure. Purification
by combi—flash using 30—100% hexanes gave 4— {3—(cyanomethy1)—3—[4—(7—{[2—
(trimethylsi1y1)ethoxy]methy1}-7H-pyrrolo[2,3 -d]pyrimidiny1)- 1 zol
y1]azetidiny1}-N-[4-fluoro(trifluoromethy1)pheny1]piperidinecarboxamide as
a powder. LC—MS: 698.1 (M+H)+.
Step B: 4-{3-(Cyan0methyl)[4—(7H—pyrr010[2,3-d]pyrimidinyl)-IH—pyrazol—I—
yUazetidin-I-yl}-N-[4-flu0r0(triflu0r0methyl)phenyl]pzperidine-I-carb0xamide
4- {3 -(Cyanomethyl)-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-
pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}-N—[4-fluoro
(trifluoromethyl)phenyl]piperidine—1—carboxamide (210 mg, 0.3 mmol) was dissolved
in a 50 M solution of trifluoroacetic acid in methylene chloride (20 mL). After being
stirred at room ature for one hour, the solvents were removed under reduced
pressure. The e was dissolved in methanol (20 mL) and ethylenediamine (1.0 g,
17 mmol). After being stirred at room temperature for one hour, the mixture was
purified by HPLC (method B) to give 4-{3-(cyanomethyl)[4-(7H-pyrrolo[2,3-
d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}-N—[4-fluoro
(trifluoromethyl)phenyl]piperidine—1—carboxamide as a white powder. LC—MS: 568.1
(M+H)+. 1H NMR (400 MHz, DMSO—ds): 8 12.10 (s, 1H), 8.76 (s, 1H), 8.63 (s, 1H),
8.36 (s, 1H), 8.18 (s, 1H), 7.55 (d, J=3.6 Hz, 1H), 7.50 (m, 1H), 7.43 (m, 1H), 7.34
(m, 1H), 7.01(d, J=3.6 Hz, 1H), 3.79 (m, 2H), 3.67 (d, J=8 Hz, 2H), 3.51 (m, 4H),
2.92(m, 2H), 2.38 (m, 1H), 1.62 (m, 2H), 1.09 (m, 2H).
Example 7. (7H-pyrrolo[2,3-d]pyrimidin-4—yl)—1H—pyrazol—l-yl](1-{[2-
(trifluor0methyl)pyrimidinyl] carbonyl}piperidinyl)azetidin
yl]acetonitrile
N/ |\
KN N
The title compound was prepared by a method analogous to the one used to
prepare Example 5. LC—MS (M+H)+: 537.2.
e 8. [trans[4-(7H-pyrrolo[2,3-d]pyrimidin-4—yl)—1H-pyrazol-l-yl](4-
{[2-(trifluoromethyl)pyrimidinyl] carbonyl}piperazin
yl)cyc10butyl] acetonitrile
A mixture of 2-(trifluoromethyl)pyrimidinecarboxylic acid (0.225 g, 1.17
mmol, prepared by hydrolysis of the methyl ester obtained from Apollo as described
in WO2006/067445), N,N,N',N'—tetramethyl-O-(7-azabenzotriazolyl)uronium
hexafluorophosphate (0.29 g, 0.76 mmol, Aldrich), and triethylamine (0.26 mL, 1.9
mmol) in tetrahydrofuran (6 mL) was prestirred for 15 minutes, followed by the
addition of piperazinyl[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo[2,3 —d]pyrimidin—4—yl)— 1 H-pyrazol— 1 clobutyl} acetonitrile (0. 188 g, 0.3 80
mmol, prepared as in Example 1b ofUS 2012/0149681, Step 1) in tetrahydrofuran (10
mL). The reaction was stirred overnight. THF was removed in vacuo. The residue was
partitioned between saturated sodium bicarbonate and ethyl acetate. The s
portion was extracted a total of three times. The combined organic extracts were dried
over sodium sulfate, decanted and concentrated. Flash chromatography, eluting with a
gradient from 0—10% MeOH in DCM was used to purify the SEM—protected
intermediate. Deprotection was effected by first stirring with roacetic acid (10
mL) in ene de (10 mL) for 2 hours, followed by evaporation of solvent in
vacuo, then stirring with methanol (6 mL, 200 mmol) containing ethylenediamine (0.5
mL, 7 mmol) overnight. The reaction mixture was partitioned n water and
ethyl acetate, and the aqueous portion was extracted a further two times with ethyl
acetate. The combined extracts were dried over sodium sulfate, filtered and
trated. Flash chromatography was used to purify product, eluting with a
gradient from 0-10% MeOH in DCM. The t was repurified preparative HPLC-
MS (C18, eluting with a gradient of H20/MeCN containing 0.1% TFA).Acetonitrile
was removed from the eluent containing the desired mass via rotary evaporation, then
the remaining aqueous solution was neutralized by the on of sodium bicarbonate
and extracted with ethyl acetate several times. The combined organic extracts were
dried over sodium sulfate, filtered and concentrated. The product was re—purifled by
preparative HPLC—MS (C18, eluting with a gradient of H20/MeCN containing 0.15%
NH4OH). The eluent containing the desired mass was frozen and lyophilized to afford
product as the free base (99 mg, 48%). 1H NMR (300 MHz, CD3OD): 5 9.13 (d, 1H),
8.71 (s, 1H), 8.66 (s, 1H), 8.39 (s, 1H), 7.88 (d, 1H), 7.50 (d, 1H), 6.98 (d, 1H), 3.89—
3.81 (m, 2H), 3.59—3.52 (m, 2H), 3.34 (s, 2H), 3.13—3.03 (m, 2H), 2.97 (tt, 1H), 2.59—
2.42 (m, 6H); 19F NMR (282 MHz, CD3OD): 5 —72.43 (s, 3F); LCMS (M+H)+: 537.0.
e 9. {trans(4-{[4-[(3-hydroxyazetidinyl)methyl]
(trifluoromethyl)pyridinyl]oxy}piperidinyl)—1-[4-(7H-pyrrolo[2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl] cyclobutyl}acetonitrile
Ex\ F
N— N
The procedure of Example 153 ofUS 2012/0149681 was ed, using
N,N—diisopropylethylamine (64 uL, 0.37 mmol) and azetidinol hloride (30
mg, 0.3 mmol, Oakwood) in the displacement step. After stirring overnight at room
temperature, ol (0.20 mL) was added to afford a homogenous solution, which
was stirred for a further 2.5 hours at room temperature and treated according to the
deprotection and purification conditions given in Example 153 of US 2012/0149681
to afford product as the free base (9.7 mg, 44%).1H NMR (400 MHz, dmso) 5 12.12
(br s, 1H), 8.81 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.59 (d, J= 3.6 Hz, 1H), 7.29 (s,
1H), 7.06 (d, J= 3.6 Hz, 1H), 6.93 (s, 1H), 5.34 (d, J= 6.4 Hz, 1H), 5.05 — 4.77 (m,
1H), 4.19 (h, J: 6.1 Hz, 1H), 3.60 (s, 2H), 3.50 (td, J= 6.1, 2.0 Hz, 2H), 3.40 (s, 2H),
3.06 — 2.92 (m, 2H), 2.86 — 2.71 (m, 3H), 2.68 — 2.53 (m, 2H), 2.38 — 2.22 (m, 2H),
2.22—2.07 (br m, 2H), 2.05—1.95 (br m, 2H), 1.75 — 1.48 (m, 2H); 19F NMR (376 MHz,
dmso) 5 —67.36 (s); LCMS (M+H)+: 608.2.
Example 10. (4—{[4-{[(2S)—2-(hydroxymethyl)pyrrolidinyl]methyl}
(trifluoromethyl)pyridinyl] 0xy}piperidinyl)—1-[4—(7H—pyrrolo [2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl] cyclobutyl}acetonitrile
The method of e 158 ofUS 2012/0149681 was followed, except that
the displacement of mesylate with amine was carried out using (2S)—pyrrolidin
ylmethanol (20 uL, 0.2 mmol, Aldrich), at room temperature overnight (8.3 mg,
59%). 1H NMR (500 MHz, DMSO) 5 12.09 (br s, 1H), 8.81 (s, 1H), 8.69 (s, 1H), 8.41
(s, 1H), 7.59 (d, J: 3.5 Hz, 1H), 7.39 (s, 1H), 7.06 (d, J: 3.6 Hz, 1H), 7.03 (s, 1H),
.00 (tt, J: 8.4, 3.9 Hz, 1H), 4.48 (s, 1H), 4.12 (d, J: 14.8 Hz, 1H), 3.45 (d, J: 15.0
Hz, 1H), 3.41 (s, 2H), 3.42—3.25 (m, 2H), 3.06 — 2.97 (m, 2H), 2.87 — 2.77 (m, 2H),
2.69 — 2.62 (m, 2H), 2.59 (dddd, J: 5.8, 5.8, 5.8, 8.1 Hz, 1H), 2.41 — 2.31 (m, 2H),
2.22 — 2.09 (m, 3H), 2.08 — 1.95 (m, 2H), 1.83 (dddd, J: 8.1, 8.1, 8.3, 12.2 Hz, 1H),
1.75 — 1.46 (m, 5H); ”P NMR (376 MHz, dmso) 5 —67.24 (s); LCMS (M+H)+: 636.3.
Example 11. {trans(4—{[4-{[(2R)(hydroxymethyl)pyrrolidinyl]methyl}-6—
(trifluoromethyl)pyridinyl]oxy}piperidinyl)—1-[4—(7H—pyrrolo[2,3-
d]pyrimidin-4—yl)—lH-pyrazolyl]cyclobutyl}acet0nitrile
0 F
The method of Example 158 of US 2012/0149681 was followed, except that
the displacement of mesylate with amine was carried out using (2R)-pyrrolidin
ylmethanol (20 ”L, 0.2 mmol, Aldrich) at room ature overnight (8.3 mg, 59%).
1H NMR (400 MHz, dmso) 5 12.14 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H),
7.60 (d, J= 3.6 Hz, 1H), 7.39 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.03 (s, 1H), 5.04 —
4.94 (m, 1H), 4.52 (t, J: 5.4 Hz, 1H), 4.12 (d, J: 14.9 Hz, 1H), 3.52 — 3.22 (m, 5H),
3.09 — 2.92 (m, 2H), 2.86 — 2.73 (m, 2H), 2.70 — 2.53 (m, 3H), 2.42 — 2.27 (m, 2H),
2.22 — 2.09 (m, 3H), 2.06 — 1.87 (m, 2H), 1.82 (dddd, J= 8.0, 8.0, 8.4, 11.9 Hz, 1H),
1.77 — 1.37 (m, 5H); 19F NMR (376 MHz, dmso) 5 —67.24 (s); LCMS : 636.3.
Example 12. 4-(4-{3-[(Dimethylamino)methyl]-5—flu0r0phenoxy}piperidinyl)—
3-[4—(7H-pyrrolo [2,3-d]pyrimidinyl)—1H-pyrazol—l-yl]butanenitrile (chiral)
Step I. 3-Flu0r0hydr0xybenzaldehyde
To a suspension of 3—fiuoro—5—hydroxybenzonitrile (1.00 g, 7.29 mmol) in
toluene (60.0 mL at —78 0C was added 1.0 M diisobutylaluminum hydride in toluene
(18.2 mL, 18.2 mmol). The ing mixture was stirred at -78 0C for 1 hour and
allowed to warm to room temperature overnight. The 1:1 mixture of ol and
water (10 mL) was added and stirred for 35 minutes. The solid was filtered and
washed with ethyl e. The filtrates were washed with water and brine then dried
over NazSO4, filtered, and concentrated. The crude product was purified with silica
gel column (eluted with 10—50% ethyl acetate/hexanes) to give the desired product
(0.77 g, 75%). 1H NMR (DMSO—ds) 8 10.49 (s, 1H), 9.88 (s, 1H), 7.10 (m, 2H), 6.87
(d, 1H).
Step 2. methylamin0)methyU—5-flu0r0phenol
To a mixture of dimethylamine hydrochloride (160 mg, 1.96 mmol) and 3—
fiuoro—5—hydroxybenza1dehyde (250.0 mg, 1.784 mmol) in methylene de (9.0
mL) was added triethylamine (323 uL, 2.32 mmol) and resin of sodium
triacetoxyborohydride (1.1 g, 2.7 mmol). The resulting mixture was stirred overnight
then filtered and concentrated. The crude was purified by silica gel column (eluting
with 0—15% methanol/DCM) to give the desired product (0.21 g, 70%). 1H NMR
(DMSO—ds) 8 6.55 (m, 2H), 6.42 (d, 1H), 2.15 (s, 6H), 1.89 (s, 2H). LCMS (M+H)+:
170.1.
Step 3. 4-(4-{3-[(Dimethylamin0)methyl]fluor0phen0xy}piperidin-I—yD-S-
[4-(7H-pyrr010[2,3-d]pyrimidinyl)-IH-pyrazol-I—yUbutanenitrile
To a mixture of 3-[(dimethylamino)methyl]fiuorophenol (158 mg, 0.934
mmol) in ene chloride (9 mL) was added Resin of triphenylphosphine (578 mg,
1.37 mmol) and di-tert-butyl azodicarboxylate (229 mg, 0.996 mmol). The mixture
was stirred for 20 minutes before adding a solution of 4-(4-hydroxypiperidinyl)
[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidinyl)-1H-
pyrazolyl]butanenitrile (300 mg, 0.6 mmol) in methylene chloride (2 mL). The
reaction was stirred at room temperature overnight. Additional resin of
triphenylphosphine (0.5 g), di-tert—butyl azodicarboxylate (0.23 g), and DCM (8mL)
were added and stirred for additional 2 hours. The vial and resin were washed with
DCM and filtered. The es were washed with 10% aq. NaOH solution. The
c layer was dried over MgSO4, filtered, and concentrated. The crude was
purified by silica gel column (eluted with 0-15% methanol/DCM) to give the SEM
protected product. LCMS (M+H)+: 633.5. To the purified product was added
methylene chloride (1.5 mL) and trifluoroacetic acid (1.5 mL, 19 mmol) and stirred
for 2 hours. The solvents were evaporated before adding methanol (3.5 mL) and
ethylenediamine (0.70 mL, 10 mmol). The ing mixture was stirred for 1 hour
then concentrated. The concentrate was taken up in DCM and washed with water,
dried over NazSO4, filtered, and concentrated to give the crude product which was
purified by chiral prep-HPLC (Chiralcel OJ-H column, 4.6 x 250mm, 5 u, 60%
ethanol/Hex, 0.5 ml/min) to afford 2 enantiomers.
enantiomer 1 (first to elute): LCMS (M+H)+: 503.3.
omer 2 (second to elute): 1H NMR (DMSO—ds) 8 8.78 (s, 1H), 8.67 (s,
1H), 8.35 (s, 1H), 7.59 (d, 1H), 6.96 (d, 1H), 6.64 (t, 3H), 4.94 (m, 1H), 4.36 (m, 1H),
3.39 (m, 2H), 3.19 (d, 3H), 2.77 (m, 3H), 2.60 (m, 1H), 2.32 (m, 2H), 2.10 (s, 6H),
1.83 (m, 2H), 1.54 (m, 2H). LCMS (M+H)+: 503.3.
Example 13. 5-{3-(Cyan0methyl)—3-[4—(7H—pyrrolo[2,3-d]pyrimidinyl)—1H—
pyrazol—l-yl] azetidin-l-yl}-N-isopropylpyrazine-Z-carb0xamide
NWWNWRN—N
NC ' \
\N N
H
Step 1: methyl 5-{3-(cyan0methyl)[4-(7—{[2-(trimethylsilyl)ethoxy]methyl}-7H-
0[2, 3-d]pyrimidinyl)-IH-pyrazol—I-yl]azetidin-I-yl}pyrazinecarb0xylate
(R)—(+)—2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (0.065 g, 0.10 mmol) was
added to a mixture of {3-[4-(7- rimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
d]pyrimidinyl)-1H-pyrazolyl]azetidin-3 -yl} acetonitrile dihydrochloride (0.50 g,
1.0 mmol), methyl 5-chloropyrazinecarboxylate (0.18 g, 1.0 mmol)(Ark Pharm,
Inc., Cat. #: AK—23920), and cesium carbonate (1.0 g, 3.1 mmol) in toluene (15.0
mL) under nitrogene, followed by palladium acetate (0.023 g, 0.10 mmol). The
reaction mixture was d at 120°C for 3 h. After cooled to r.t., the reaction mixture
was filtered throught a pad of celite, washed with ethyl acetate. The filtrate was
concentrated under reduced pressure. The e was purified by flash
chromatography on a silica gel column with ethyl acetate in dichloromethane (0—70%)
to afford the desired product (0.31 g, 55%). LCMS (M+H)+ : m/z = 546.3.
Step 2: cyan0methyD[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-
pyrr010[2, 3-d]pyrimidinyl)-IH-pyrazol—I-yl]azetidin-I-yl}pyrazinecarb0xylic
acid
A mixture of methyl 5- {3-(cyanomethyl)[4-(7-{[2-(trimethylsilyl)ethoxy]-
methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)—1H-pyrazolyl]azetidinyl}pyrazine
carboxylate (0.31 g, 0.57 mmol), lithium hydroxide monohydrate (0.060 g, 1.4
mmol) in methanol (6.0 mL) and water (2.5 mL) was stirred at 30°C overnight. The
mixture was adjuested to pH = 4 with aqueous HCl, and concentrated under reduced
pressure to remove MeOH. The resulted solid was filtered, washed with water and
ether, and then dried in vacuum to afford the d product (0.25 g, 83%). LCMS
(M+H)+ : m/z = 532.3
Step 3: 5-{3-(cyanomethyl)[4-(7H-pyrr010[2,3-d]pyrimidinyl)-IH-pyrazol—I-
yUazetidin-I-yl}-N-isopropylpyrazine-Z—carboxamide
Triethylamine (15 uL, 0.11 mmol) was added to a mixture of 5—{3—
methyl)—3 - [4-(7- {[2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo[2,3 -
d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}pyrazine—2-carboxylic acid (19.4
mg, 0.03 65 mmol) and benzotriazolyloxytris(dimethylamino)phosphonium
hexafluorophosphate (19 mg, 0.044 mmol) and 2-propanamine (3.2 mg, 0.055
mmol) in methylene chloride (1.3 mL). The reaction mixture was stirred at r.t.
overnight. The reaction mixture was worked up with aqueous NaHCO3, and extracted
with methylene chloride (2 x 2 mL). The combined organic layers were washed with
water (1 mL) and concentrated under reduced pressure. The e was used for next
step without further cation. LCMS (M+H)+ : m/z = 573.3.
Methylene chloride (1.3 mL) and trifluoroacetic Acid (0.6 mL) were added to
the above intermediate. The reaction mixture was stirred at r.t. for 1.5 h. The mixture
was concentrated under reduced re. The residue was dissolved in methanol (1.3
mL). To the solution was added ethylenediamine (0.086 mL). The reaction mixture
was stirred at r.t. for 2 h., and purified by RP-HPLC (pH = 10) to afford the desired
product. LCMS (M+H)+ : m/z = 443.2. 1H NMR (400 MHz, DMSO—d6): 5 12.15 (br,
1H), 8.97 (s, 1H), 8.68 (s, 1H), 8.63 (d, J = 1.2 Hz, 1H), 8.46 (s, 1H), 8.12 (d, = 8.4
Hz, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.60 (dd, J = 3.3, 2.4 Hz, 1H), 7.07 (dd, J = 3.4, 1.7
Hz, 1H), 4.81 (d, J = 9.8 Hz, 2H), 4.53 (d, J = 9.6 Hz, 2H), 4.13—4.02 (m, 1H), 3.78 (s,
2H), 1.14 (d, J = 6.8 Hz, 6H).
e 14. Cyanomethyl)—3-[4—(7H—pyrrolo[2,3-d]pyrimidinyl)—1H—
pyrazol—l-yl] azetidin-l-yl}-2,5-diflu0r0-N-[(1S)-2,2,2-trifluoro
methylethyl]benzamide
le\ \
N N
Step I .‘ 4-chlor0-2, 5-diflu0r0-N-[(IS)-2, 2, 2-triflu0r0-I-methylethyl]benzamide
4—Chloro—2,5—difluorobenzoyl de (29.6 mg, 0.140 mmol) (Oakwood,
Cat.#: 001628) was added to a mixture of (2S)—l,l, l-trifluoropropanamine
hydrochloride (20.0 mg, 0.134 mmol) (SynQuest Lab, Cat.#: 3130—7—S1) and
diisopropylethylamine (58 ”L, 0.33 mmol) in dichloromethylene (4.0 mL) at 0 °C.
The reaction mixture was stirred at room temperature for 30 min., worked up with
ted aqueous NaHCO3, and extracted with dichloromethylene (3x10 mL). The
ed organic layers were washed with brine, dried over MgSO4, filtered and
concentrated under reduced pressure to afford the desired product which was directly
used in the next step reaction without further purification. LCMS (M+H) +: m/z =
288.0/290.0.
Step 2: 4-{3-(cyan0methyD[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-
0[2,3-d]pyrimidinyl)-IH—pyrazol—I—yUazetidin-I—yl}-2,5-diflu0r0-N-[(IS)-
2, 2, 2-triflu0r0-I-methylethyl]benzamide
(R)—(+)—2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (8.3 mg, 0.013
mmol) was added to a mixture of {3-[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrrolo [2,3 -d]pyrimidinyl)-1H-pyrazolyl]azetidin-3 -yl} acetonitrile
dihydrochloride (65 mg, 0.13 mmol), 4—chloro-2,5—difluoro—N—[(1S)—2,2,2—trifluoro—1—
methylethyl]benzamide (0.14 mmol), and cesium carbonate (0.13 g, 0.40
mmol) in toluene (4.0 mL) under N2, followed by palladium acetate (3.0 mg, 0.013
mmol). The reaction mixture was stirred at 130 0C for 5 h. After the reaction mixture
was cooled to room temperature, the mixture was worked up with water, and
extracted with ethyl acetate (3 x10 mL). The combined organic layers were washed
with brine, dried over MgSO4, filtered and concentrated under reduced pressure to
afford the crude product which was directly used in the next step reaction without
further purification. LCMS (M+H) +: m/z = 661.2.
Step 3: 4-{3-(cyanomethyl)[4-(7H—pyrr010[2,3-d]pyrimidinyl)-IH—pyrazol—I-
yUazetidin-I—yl}-2, 0r0-N-[(IS)-2, 2, u0r0-I—methylethyUbenzamide
Boron trifluoride te (0.051 mL, 0.40 mmol) was added to a solution of
4- {3 -(cyanomethyl)[4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo[2,3 -
d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}-2,5-difluoro-N—[(1S)—2,2,2-
trifluoromethylethyl]benzamide in acetonitrile (1.0 mL) at 0 0C under N2. The
reaction mixture was stirred at room temperature for 3 h. (LCMS (M+H)+: m/z =
561.3). Then the mixture was cooled to 0 0C, water (0.13 mL) was added. After 30
min, 5.0 M um hydroxide in water (0.2 mL, 1 mmol) was added slowly at 0
0C over 5 min. The reaction mixture was stirred at room temperature overnight, and
purified by RP-HPLC (pH = 10) to afford the desired product. LCMS (M+H) +: m/z =
531.0. 1H NMR (400 MHz, 6): 5 12.62 (br, 1H), 9.07 (s, 1H), 8.84 (s, 1H),
8.55 (s, 1H), 8.51 (dd, J = 8.8, 1.2 Hz, 1H), 7.78 (br, 1H), 7.35 (dd, J = 12.6, 6.5 Hz,
1H), 7.23 (d, J = 1.9 Hz, 1H), 6.65 (dd, J = 11.9, 7.3 Hz, 1H), 4.76 (m, 1H), 4.70 (d, J
= 9.3 Hz, 2H), 4.44 (d, J = 9.2 Hz, 2H), 3.76 (s, 2H), 1.30 (d, J = 7.1 Hz, 3H).
Example 15. 5-{3-(Cyan0methyl)—3-[4—(1H—pyrrolo[2,3-b]pyridinyl)—1H—
l—l-yl] azetidin-l-yl}-N-isopropylpyrazine-Z-carb0xamide
N::30 J\,
N “we
N N
/ W
Step 1: methyl 5-{3-(cyan0methyD[4-(I-{[2-(trimethylsilyl)ethoxy]methyl}-1H-
pyrr010[2, 3-b]pyridinyl)-IH-pyrazol—I-yl]azetidin-I-yl}pyrazinecarb0xylate
N,N—Diisopropylethylamine (1.0 mL, 6.0 mmol) was added to a e of
{3-[4-(1- {[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3 -b]pyridinyl)-1H-
pyrazolyl]azetidinyl}acetonitrile dihydrochloride (0.96 g, 2.0 mmol) and methyl
-chloropyrazinecarboxylate (0.34 g, 2.0 mmol) in 1,4-dioxane (15 mL). The
reaction mixture was stirred at 120 0C overnight. The mixture was worked up with
saturated aqueous , and extracted with dichloromethylene (3x 20 mL). The
combined organic layers were washed with brine, dried over MgSO4, ed and
concentrated under reduced pressure. The residue was purified by flash
chromatography on a silica gel column with ethyl acetate in hexanes (0—60%) to
afford the desired product (0.13 g, 12%). LCMS (M+H) +: m/z = 545.2.
Step 2: cyan0methyD[4-(I-{[2-(trimethylsilyl)ethoxy]methyl}-1H-
pyrr010[2, 3-b]pyridinyl)-IH-pyrazol—I—yUazetidin-I-yl}pyrazinecarb0xylic acid
A reaction mixture of methyl 5-{3-(cyanomethyl)[4-(1- {[2-
(trimethylsilyl)ethoxy]methyl} - 1 H-pyrrolo [2,3 -b]pyridinyl)-1H-pyrazol
yl]azetidinyl}pyrazinecarboxylate (0.13 g, 0.24 mmol), lithium hydroxide
monohydrate (0.025 g, 0.60 mmol) in methanol (4.0 mL), THF (2.0 mL) and water
(1.0 mL) was stirred at 40 0C for 3 h. The mixture was adjusted to pH = 4 with 2.0 N
HCl aqueous solution, and trated under reduced pressure to remove MeOH and
THF. The precipitate formed was filtered, washed with water and ether, and dried in
vacuum to afford the desired product (0.100 g, 79%). LCMS (M+H)+ : m/z = 531.4.
Step 3: 5-{3-(cyan0methyD[4-(IH-pyrr010[2,3-b]pyridinyl)-IH-pyrazol—I—
yUazetidin-I-yl}-N-isopropylpyrazinecarb0xamide
N,N—Diisopropylethylamine (19 uL, 0.11 mmol) was added to a mixture of 5-
{3-(cyanomethyl)—3 -[4-(1- {[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,3-
b]pyridinyl)-1H-pyrazolyl]azetidinyl}pyrazinecarboxylic acid (19.4 mg,
0.0365 mmol), benzotriazolyloxytris(dimethylamino)phosphonium
hexafluorophosphate (19 mg, 0.044 mmol) and 2-propanamine (3.2 mg, 0.055
mmol) in DMF (1.0 mL). The reaction mixture was stirred at room temperature
ght. The reaction mixture was worked up with saturated aqueous NaHCO3, and
extracted with dichloromethylene (3x 20 mL). The combined organic layers were
washed with brine, dried over MgSO4, filtered and concentrated under reduced
pressure. The residue was treated with methylene de (1.3 mL) and TFA (1.3
mL). The mixture was stirred at room temperature for 1.5 h., and concentrated under
reduced pressure. The e was dissolved in methanol (1.3 mL), and treated with
ethylenediamine (0.086 mL, 1.3 mmol). The resulting mixture was stirred at room
ature for 2 h, and then purified by RP-HPLC (pH = 10) to afford the desired
product. LCMS (M+H) +: m/z = 442.1. 1H NMR (400 MHz, DMSO— d6): 5 12.19 (br,
1H), 8.99 (s, 1H), 8.66 (d, J = 1.4 Hz, 1H), 8.47 (s, 1H), 8.32 (d, J = 5.7 Hz, 1H), 8.14
(d, J = 8.4 Hz, 1H), 8.00 (d, J =1.4 Hz, 1H), 7.67 (dd, J = 3.2, 2.7 Hz, 1H), 7.54 (d, J
= 5.5 Hz, 1H), 7.09 (dd, J = 3.5, 2.7 Hz), 4.82 (d, J = 10.0 Hz, 2H), 4.56 (d, J =10.0
Hz, 2H), 4.10 (m, 1H), 3.79 (s, 2H), 1.17 (d, J = 6.4 Hz, 6H).
Example 16: s{[6—(2-hydr0xyethyl)—2-(trifluoromethyl)pyrimidin
yl]0xy} cyclohexyl)—3-[4—(7H-pyrrolo [2,3-d]pyrimidinyl)—1H-pyrazol—l-
yl]azetidinyl} acetonitrile tris(trifluoroacetate)
\ \ . 2.5 CF3C02H
Step I hyl [6—(I , 4-di0xaspir0[4. 5]dec-S-yloxy)(trifluoromethybpyrimidin-
4yl]malonate
To a mixture of tetrahydrofuran (40 mL) and NaH in mineral oil (1.1 g,
28 mmol) at 0 0C was added ethyl malonate (4.2 mL, 28 mmol), dropwise. 4-chloro—
6-(1,4-dioxaspiro[4.5]decyloxy)(trifluoromethyl)pyrimidine (described in
Example 1 ofUS 2013/0045963, Step 1) (3.75 g, 11.1 mmol), was then added. The
reaction mixture was stirred at 64 0C. After 3 hours, HPLC & LCMS analysis
showed 70% reaction completion. Heated for another 6 hours, and then cooled to 20
OC. Only a trace of decarboxylation t formed. The reaction was diluted with
aqueous bicarbonate, and extracted with EtOAc. The EtOAc extract was washed with
brine, dried over NazSO4, and evaporated in vacuo to give 8.5 g oil (includes excess
ethyl malonate and mineral oil). The crude product was purified by
chromatography on a 120 g silica gel column, using solvent A: hexane; solvent B:
EtOAc; flow 60 mL/min; A, 3 min; Gradient to 40%B in 40min; detector set at
254nm; collected 47 mL fractions; retention time, 28 min. The ed fractions
were evaporated to give 4.6 g, colorless oil, 90 % yield. 1H NMR (300 MHz, :
57.05 (s, 1H); 5.30 (m, 1H, OCH); 4.85 (s, 1H, CH); 4.25 (m, 2H, OCHz); 3.95 (s,
4H, OCHz); 1.6—2.1 (m, 8H); 1.28 (t, 3H, CH3).
Stp 2: Ethyl [6—(I,4-di0xaspir0[4.5]dec-8—yloxy)(trzflu0r0methyl)pyrimidin
yl]acetate
Diethyl [6-(1,4-dioxaspiro[4.5]decyloxy)(trifluoromethyl)pyrimidin
yl]malonate (4.60 g, 9.95 mmol), was ved in ethanol (46 mL). Water (18 uL,
1.0 mmol) and 21% Sodium ethoxide in ethanol (0.37 mL, 1.0 mmol) were added.
The reaction mixture was d at 75 0C for 1 hour. HPLC & LCMS analysis
showed 60% oxylation. The heating was continued for another 2 hours
ion complete). The reaction was diluted with aqueous bicarbonate, and extracted
with EtOAc. The EtOAc t was washed with brine, then dried (NazSO4), and
evaporated in vacuo to 3.4 g oil (88% yield). LCMS, HPLC, & NMR showed it to be
clean enough to proceed. 1H NMR (400 MHz, DMSO—Ds): 57.20 (s, 1H); 5.20 (m,
1H, OCH); 4.10 (q, 2H, OCH2); 3.89 (s, 2H, CH2); 3.85 (s, 4H, OCH2); 1.5—2.0 (m,
8H); 1.15 (t, 3H, CH3). HPLC showed it to have UVmax 222 & 252nm.
Step 3: 2-[6—(I,4-di0xaspir0[4.5]dec-8—yloxy)(trzfluoromethybpyrimidin
yl]ethanol
Ethyl [6-(1,4-dioxaspiro[4.5]decyloxy)(trifluoromethyl)pyrimidin
y1]acetate(3.0g) was dissolved in tetrahydrofuran (40 mL), and cooled in an ice
bath. Sodium tetrahydroborate (884 mg, 23.4 mmol) was added followed by
methanol (4.8 mL, 120 mmol), in portions. The reaction e was stirred for 20
min, removed the ice bath, and stirred at 21 0C for 0.5 hour. HPLC &
LCMS showed no remaining ester, and showed conversion to the desired M+H 349;
and also showed several over ion products (at least one of which has no UV
ance). The reaction mixture was quenched with water and evaporated. The
reaction mixture was diluted with aqueous bicarbonate and EtOAc, and stirred for 0.5
hour. The EtOAc layer was washed with brine, dried (NazSO4), and evaporated to
give 3.0 g oil. The product was purified by chromatography on a 120 g silica
gel column, using solvent A: hexane; solvent B: 3%iPA/EtOAc; flow 60 mL/min;
A, 3 min; Gradient to 50%B in 30 min, then 50%B for 15 min; detector set at 254
nm; collected 47 mL fractions; retention time, 34 min. evaporated to yield 1.5
g, a light yellow s oil, 56% yield. 1H NMR (300 MHz, DMSO—Ds): 57.10 (s,
1H); 5.20 (m, 1H, OCH); 4.71 (t, 1H, OH); 3.85 (s, 4H, OCHz); 3.72 (q, 2H, OCHz);
2.85 (t, 2H, CH2); 1.5—2.0 (m, 8H).
Step 4: 4-{[6—(2-hydr0xyethyl)(trzfluoromethybpyrimidinyl]0xy}cyclohexanone
2-[6-(1,4-Dioxaspiro[4.5]decyloxy)(trifluoromethyl)pyrimidin
yl]ethanol
was ved in acetone (60 mL, 900 mmol), and 5.0 M hydrogen chloride in water
(20 mL, 98 mmol) was added and stirred for 17 hours. LCMS and HPLC analysis
showed nearly complete conversion to M+H 305. Aqueous bicarbonate was added
and the reaction mixture was stirred, then concentrated. This mixture was extracted
with EtOAc. The EtOAc was dried (NazSO4), and evaporated in vacuo to give
1.3 g light yellow viscous oil (used in the next reaction without purification). 1H NMR
(300 MHz, : 56.80 (s, 1H); 5.60 (m, 1H, OCH); 4.06 (t, 2H, OCH2); 3.04 (t,
2H, CH2); 2.61 (m, 2H); 2.45 (m, 2H); 2.25 (m, 2H).
Step 5 .‘ {I -(4- {[6- (2-hydr0xyethyD(trifluoromethyl)pyrimidinyl]oxy}cyclohexyl)-
7—{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrr010[2,3-d]pyrimidinyl)-IH—
pyrazol—I—yUazetidinyl}acet0nitrile
{3 - [4-(7- {[2-(Trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidin
yl)-1H-pyrazolyl]azetidin-3 -yl}acetonitrile dihydrochloride (1.9 g, 3.9 mmol), and
4- { [6-(2-hydroxyethyl)(trifluoromethyl)pyrimidinyl]oxy} cyclohexanone (1.3 g,
4.3 mmol), in dry tetrahydrofuran (36 mL) were stirred for 15 min under nitrogen.
Sodium triacetoxyborohydride (1.7 g, 8.2 mmol) was then added. The mixture was
stirred at 20 0C for 16 hours. HPLC and LCMS analysis showed clean conversion
to the trans and cis products (M+H 698; 1:1 ratio). The reaction was ed with
water, concentrated, stirred with 20% KHCO3 and extracted with ethyl acetate, dried
(NazSO4), filtered, and evaporated to give 2.8 g. The isomeric ts were
separated by prep LCMS using a Waters instrument and a 30mm>< 100mm Xbridge
C18 column; 60mL/min; 55% CH3CN—H20 H4OH); 0.5min; 4.5 gradient to
72%; 24 runs; retention time trans isomer, 4.6 min; cis isomer, 5.4 min. The isolated
cis isomer contained <1% residual trans isomer. Yield 1.00 g cis isomer, 37% yield.
1H NMR (500 MHz, CDCl3; also COSY, HSQC, and HMBC): 58.83 (s, 1H); 8.40 (s,
1H); 8.28 (s, 1H); 7.40 (m, 1H); 6.80 (m, 1H); 6.67 (s, 1H); 5.64 (s, 2H, SEM); 5.17
(m, 1H, OCH); 4.01 (t, 2H, OCHz); 3.74 (s, 2H, NCH); 3.59 (m, 2H, NCH); 3.55 (t,
2H, SEM); 3.38 (s, 2H, CHzCN); 2.95 (t, 2H, CH2); 2.30 (m, 1H, NCH); 2.15 (m,
2H); 1.84 (m, 2H); 1.50 (m, 2H); 1.30 (m, 2H); 0.90 (t, 2H, SEM); —0.92 (s, 9H,
SEM).
Step 6: S{[6-(Z-hydroxyethyl)(trzfluoromethybpyrimidin
yl]0xy}cyclohexyl)[4-(7H—pyrr010[2, 3-d]pyrimidinyl)-IH—pyrazol-I—yUazetidin-
3-yl}acet0nitrile rzflu0r0acetate)
{ 1-(4- { [6-(2-Hydroxyethyl)—2-(trifluoromethyl)pyrimidin
yl] oxy} cyclohexyl)-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -
d]pyrimidinyl)-1H-pyrazol-1 -yl]azetidin-3 -yl} acetonitrile isomer was
dissolved in methylene chloride (18 mL) and trifluoroacetic acid (TFA, 18 mL, 230
mmol) and was stirred for 1.0 hour. The solution was concentrated to remove TFA.
LCMS showed conversion to the hydroxymethyl intermediate, M+H 598, some
of its TFA ester, M+H 694, and <5% residual SEM. The residue was dissolved
in methanol (36 mL) and 15.0 M um hydroxide in water (9.0 mL, 130 mmol)
was added. The solution was stirred at 21 °C for 18 hours. HPLC & LCMS showed
no remaining M+H 598 peak or TFA ester. The solution was evaporated. Ammonium
trifluoroacetate was removed by adding aqueous bicarbonate and extracting the
product with EtOAc. The combined EtOAc extract was evaporated to give 0.96 g.
This was dissolved in 70 mL of 10% H20/ACN containing 1.5 equiv TFA (180
uL). The product was isolated by prep LCMS using a Waters Fraction-Linx
instrument and a 30mm>< 100mm Sunfire C18 column; 60 mL/min; 15% ACN—HzO
(0.1%TFA), 0.5 min; 4.5 min gradient to 33%; detector set at m/z 568; 14
runs; retention time 5.0 min. HPLC showed UVmax 224, 252, 294, and 318 nm. The
combined fractions were freeze—dried. Yield 1.0 g white solid (80%
yield). NMR showed it to be the 2.5 TFA salt. 1H NMR (500 MHz, CD3CN; also
COSY, HSQC, and HMBC): 510.84 (s, 1H, NH); 9.00 (s, 1H); 8.90 (s, 1H); 8.56 (s,
1H); 7.66 (m, 1H); 7.10 (m, 1H); 6.86 (s, 1H); 5.39 (m, 1H, OCH); 4.86 (brs, 2H,
NCH); 4.66 (m, 2H, NCH); 3.90 (t, 2H, OCH2); 3.78 (s, 2H, ; 3.39 (m, 1H,
NCH); 2.92 (t, 2H, CH2); 2.20 (m, 2H); 1.92 (m, 2H); 1.76 (m, 4H). 19F NMR (400
MHz, DMSO—Ds): 5— 69.8 (s); — 74.8 (s, TFA); LCMS calculated for C27H29F3N90z
(M+H)+: m/z =568.24
Example 17: {1-(cis{[4-[(ethylamino)methyl](trifluoromethyl)pyridin
yl]0xy} cyclohexyl)—3-[4-(7H-pyrrolo[2,3-d]pyrimidinyl)—1H—pyrazol—l-
yl]azetidinyl} itrile tris(trifluoroacetate)
N \
\\ 0gm\7C/N
N / H
/ F F
/ F
N \ \ . 3 CF3COZH
'k /
N N
Step I: [2-[(ciS{3-(cyan0methyD[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-
pyrr010[2,3-d]pyrimidinyl)-IH—pyrazol—I—yUazetidin-I—yl}cyclohexyl)0xy]-6—
uoromethybpyridin-4—yl]methyl methanesulfonate
{ 1—(cis {[4-(Hydroxymethyl)—6-(trifluoromethyl)pyridin
yl] oxy} cyclohexyl)-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} rrolo [2,3 -
d]pyrimidinyl)-lH-pyrazol-l-yl]azetidinyl}acetonitrile (from Example 64 ofUS
2013/0045963, 145.0 mg, 0.2124 mmol) was dissolved in methylene chloride (2.93
mL) and was cooled to 0 °C. To that N,N—diisopropylethylamine (60.5 uL, 0.347
mmol) was added followed by methanesulfonyl de (23 uL, 0.30 mmol). The
reaction was stirred at 0 0C for 1 hour. Then the reaction mixture was worked up with
EtOAc and used in the next reaction. MS(ES):761(M+1).
Step 2:{I—(cis{[4—[(ethylamin0)methyl](trzfluoromethybpyridin-Z-
yl]0xy}cyclohexyl)[4-(7H—pyrr010[2, 3-d]pyrimidinyl)-IH—pyrazol—I—yUazetidin-
3-yl}acet0nitrile tris(trzflu0r0acetate)
iS—4— {3 -(Cyanomethyl)[4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-
pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -yl] azetidin- l -yl}cyclohexyl)oxy]—6-
(trifluoromethyl)pyridinyl]methyl methanesulfonate (50 mg, 0.06571 mmol) was
dissolved in l,4-dioxane (2.5 mL) and, 2.0 M ethylamine in THF (300 uL,
0.6 mmol) was added. The reaction was stirred at 25 °C for 16 hours at which time
LCMS analysis showed mainly product. The t were purified by LC,
evaporated, and deprotected as in Example 1 of US 2013/0045963 and purified by LC
to give the product. 1H NMR (400 MHz, CD3OD) 5 9.08 (s, 1H), 8.87 (s, 1H), 8.58 (s,
1H), 7.78 (d, 1H), 7.50 (s, 1H), 7.25 (d, 1H), 7.13 (s, 1H), 5.38 (m, 1H), 5.08 (d, 2H),
4.80 (d, 2H), 4.27 (s, 2H), 3.74 (s, 2H), 3.50 (m, 1H), 3.16 (q, 2H), 2.24 (m, 2H), 2.01
(m, 2H), 1.76 (m, 4H), 1.34 (t, 3H). 19F NMR (376 MHz, CD3OD) 5 —70.52 (s), —77.49
(s). MS(ES):580(M+1).
Example 18: {1-(cis{[4-(1-hydroxymethylethyl)—6-(trifluoromethyl)pyridin-
2-yl]oxy} cyclohexyl)—3-[4—(7H-pyrrolo ]pyrimidin-4—yl)—1H-pyrazol—lyl
]azetidinyl}acetonitrile bis(triflu0r0acetate)
N(O, I\
/ F
/ FF
N\ \
. 2 CF3COZH
'k /
N N
Step I: 2-chloro-6—(trifluoromethyl)isonicotinic acid
2—Chloro—6—(trifluoromethyl)pyridine (1.0 g, 5.51 mmol, Oakwood
Products) was dissolved in tetrahydrofuran (20 mL) and 1.0 M lithium chloride -
chloro(2,2,6,6-tetramethylpiperidin-l-yl)magnesium (1:1) in THF (6.610 mL, 6.610
mmol, Aldrich Co.) was added at 25 OC. The reaction was stirred at 25 0C for 1 hour
and was cooled to
—78 °C. The reaction was stirred at —78 °C for 1 hour and allowed to warm to room
temperature, quenched with water, and was partitioned n 1N NaOH and
ether. The phases were separated and the aqueous phase was washed with additional
ether and acidified with concentrated HCl to pH~l and extracted with ether. The
combined organic phase was washed with water, saturated NaCl, dried over MgSO4,
filtered, and evaporated to dryness to provide the crude product. NMR analysis
showed that it consisted of a ~2:l mixture of the para and meta carboxylic acids. The
mixture was carried over to the next on. 440 MHz NMR(CDCl3) 5 8.17 (s, 1H),
8.11 (s, 1H).
Step 2: ethyl 2-chIoro-6—(triflu0r0methyl)isonicotinate and ethyl 2-chlor0
(trzj’luoromethybnicotinate
In a vial, 2-chloro(trifluoromethyl)nicotinic acid (0.98 g, 4.4 mmol) and 2-
chloro—6—(trifluoromethyl)isonicotinic acid (1.85 g, 8.2 mmol) were dissolved in ethyl
orthoformate (5.0 mL, 30.1 mmol) and heated at 120 0C for 5 hours at which time
TLC analysis showed that most of the starting al had been ed and the
products were formed. The reaction mixture was evaporated in vacuo and the residue
was purified by silica gel chromatography using 10% EtOAc/hexanes to give the two
ethyl ester products. 1H NMR (400 MHz, CDCl3): 5 8.14 (s, 1H), 8.08 (s, 1H), 4.47
(q, 2H), 1.44 (t, 3H).
Step 3: 2-[2-chZoro(trzj’luoromethybpyridin-4—yl]pr0panol
Ethyl 2-chloro(trifluoromethyl)isonicotinate (0.35 g, 1.4 mmol) was
dissolved in tetrahydrofuran (13.8 mL) and was cooled to —78 0C, then 3.0 M
methylmagnesium bromide in ether (1.4 mL, 4.1 mmol) was added. The reaction was
stirred at -78 0C for 3 hours at which time LCMS analysis showed absence of starting
material. The reaction was ed with saturated NH4Cl and was partitioned
between water/ 1 N HCl and EtOAc, the phases were separated and the s phase
was washed with additional EtOAc. The combined organic phase was washed with
water, saturated NaCl, dried over MgSO4, filtered and evaporated to dryness to
provide the crude product. NMR is showed that it consisted of a ~1 :1 mixture
of the alcohol and the methyl ketone intermediate. The crude material used in the next
reaction without purification. . NMR 400 MHz NMR(CDC13): 5 7.70 (s, 1H), 7.63 (s,
1H), 1.60 (s, 6H)
Step 4: 2-[2-(1,4-di0xaspir0[4.5]decyloxy)(trzfluoromethybpyridinyl]pr0pan-
2-0]
1,4-Dioxaspiro[4.5]decan—8—ol (0.25 g, 1.58 mmol) and 2—[2—chloro—6—
(trifluoromethy1)pyridin—4—y1]propan—2—ol (0.2 g, 0.835 mmol) were dissolved in
tetrahydrofuran (2 mL) and cooled to 0 OC and a 60% mixture of sodium hydride
(70.0 mg, 1.75 mmol) in mineral oil was added and the on was d for
minutes at 0 OC and at 25 0C for 60 hours at which time TLC analysis indicated the
presence of some product. The reaction was quenched with water, and was ted
with ethyl acetate and the organic extracts were washed with water, saturated NaCl,
dried (MgSO4), and evaporated in vacuo. The residue was purified by LC (pH 2) to
give the product. MS(ES):362 (M+1).
Step 5: 4-{[4—(I-hydr0xy-I-methylethyl)(trzfluoromethybpyridin-Z
yl]0xy}cyclohexan0ne
2-[2-(1,4-Dioxaspiro[4.5]decyloxy)(trifluoromethyl)pyridin
y1]propan—2—ol (0.049 g, 0.14 mmol) was dissolved in acetone (3.7 mL). A solution
of 12.0 M en chloride in water (0.43 mL, 5.2 mmol) was added and was stirred
at 25 °C for 16 hours at which time LCMS showed about 70% reaction was complete.
An additional 12.0 M hydrogen chloride in water (0.43 mL, 5.2 mmol) was added and
was d for 3 hours; LCMS showed ~90% reaction was complete and
was quenched into excess , extracted with EtOAc and the organic extract was
evaporated to give the product. This was used in the next reaction without
purification. MS(ES):318 (M+l).
Step 5 .‘ {I—(cis{[4-(I-hydr0xy-I—methylethyb(trzfluoromethybpyridin-Z-
yl]0xy}cyclohexyl)[4-(7-{[2-(trimethylsilybethoxy]methyl}- 7H-pyrr010[2, 3-
d]pyrimidinyl)-IH-pyrazol—I-yl]azetidinyl}acet0nitrile
{3 - [4-(7- {[2-(Trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidin
yl)— lH-pyrazol-l-yl]azetidin-3 etonitrile dihydrochloride (55.3 mg, 0.115
mmol) and 4- {[4-(1-hydroxy-l-methylethyl)—6-(trifluoromethyl)pyridin
yl]oxy}cyclohexanone were dissolved in dry l,2—dichloroethane (1.38 mL) and were
d for 5 min and sodium triacetoxyborohydride (86.1 mg, 0.406 mmol) was
added. The on mixture was stirred at 25 0C for 16h, at which time LCMS
analysis showed mainly the two diastereomeric products. The reaction was quenched
with water, neutralized with NaHCO3 and extracted with ethyl acetate and the solvent
was evaporated. The residue was purified by LCMS (pH 10) and the fractions
containing the second peak were combined and evaporated to give {l—(cis—4— {[4—(1—
hydroxy- l -methylethyl)(trifluoromethyl)pyridinyl] oxy} cyclohexyl)-3 - [4-(7- { [2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -
yl]azetidinyl} acetonitrile. The first peak was also isolated to give ans { [4-
(l-hydroxy- l -methylethyl)(trifluoromethyl)pyridinyl] oxy} cyclohexyl)-3 - [4-(7-
{[2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -
yl]azetidinyl}acetonitrile. MS(ES): 7l2(M+l).
Step 6: {I—(cis{[4-(I-hydr0xy-I—methylethyb(trzfluoromethybpyridin-Z-
yl]0xy}cyclohexyl)[4-(7H-pyrr010[2, 3-d]pyrimidinyl)-IH-pyrazol—I—yUazetidin-
cet0nitrile bis(triflu0r0acetate)
{ l-(cis {[4-( l -Hydroxy- l -methylethyl)(trifluoromethyl)pyridin
yl] oxy} cyclohexyl)-3 - [4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -
d]pyrimidin—4—yl)— azol— l —yl]azetidin—3 —yl} itrile was deprotected as
described in Example 1 of US 2013/0045963 and was purified by liquid
chromatography (pH 2) to give l-(cis{[4-(l-hydroxy-l-methylethyl)
(trifluoromethyl)pyridinyl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3-d]pyrimidin
yl)-lH-pyrazol-l-yl]azetidinyl}acetonitrile bis(trifluoroacetate. In a similar manner
{ l-(trans {[4-(1-hydroxy-l-methylethyl)—6-(trifluoromethyl)pyridin
yl] oxy} cyclohexyl)-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidinyl)- lH-pyrazol- l -yl]azetidin-
3-yl}acetonitrile bis(trifluoroacetate) was prepared and characterized. 1H NMR (400
MHz, CD3OD) 5 9.07 (s, 1H), 8.87 (s, 1H), 8.59 (s, 1H), 7.78 (d, J: 3.7 Hz, 1H),
7.44 (s, 1H), 7.24 (d, J: 3.7 Hz, 1H), 7.05 (s, 1H), 5.35 (s, 1H), 5.09 (d, J: 12.2 Hz,
2H), 4.82 (d, J: 12.2 Hz, 2H), 3.72 (s, 2H), 3.5 (m, 1H), 2.27 (m, 2H), 2.0 (m, 2H),
1.74 (m, 4H), 1.50 (s, 6H). : 58l(M+l).
Examples 19 and 20 below were prepared analogously to the procedure of
Example 17.
F /
F \ /
N 0“
O N-N
”N \ /
N N
{l—(cis—4— { [4— { [(3 R)-3 -hydroxypyrrolidin- l -
yl]methyl} (trifluoromethyl)pyridin
l9 ”pf-Na 622 yl]oxy} cyclohexyl)-3 -[4-(7H-pyrrolo[2,3-
0H midinyl)- l H-pyrazol- l -yl] in-3 -
yl} acetonitrile pentakis(trifluoroacetate)
{l—(cis—4— { [4— { [(3 S)—3 -hydroxypyrrolidin- l -
yl]methyl} (trifluoromethyl)pyridin
yl]oxy} exyl)-3 H-pyrrolo[2,3-
d]pyrimidinyl)- l H-pyrazol- l -yl] azetidin-3 -
l acetonitrile tris trifluoroacetate
Example 21. {trans(4—{[4-({[(1S)hydroxy-l-methylethyl]amino}methyl)—6-
(trifluoromethyl)pyridinyl] oxy}piperidinyl)—1-[4—(7H—pyrrolo [2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl] cyclobutyl}acetonitrile
isopropylethylamine (9.4 uL, 0.054 mmol) and methanesulphonic
anhydride (7.9 mg, 0.045 mmol) were added to a solution of —3 —(4—{[4—
(hydroxymethyl)(trifluoromethyl)pyridinyl]oxy}piperidin- l -yl)- l - [4-(7- { [2-
(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo [2,3 -d]pyrimidinyl)- l H-pyrazol- l -
lobutyl}acetonitrile (10.0 mg, 0.018 mmol, Peak 1 from Intermediate Example
A2 ofUS 2014/0005166, Step F) in methylene chloride (0.30 mL) and the mesylate
formation was stirred for 30 minutes. The solvent was removed in vacuo and the
residue was redissolved in a mixture of tetrahydrofuran (0.30 mL) and methanol (0.10
mL) and (2S)—2—aminopropan—l-ol (20. uL, 0.27 mmol, Acros) was added. The
reaction mixture was stirred at 40 °C ght. Solvent was removed in vacuo and
the crude product was deprotected by stirring with 1:1 TFA:DCM for one hour, then
concentrated and stirred with ethylenediamine (0.10 mL) in methanol (10 mL) until
the deprotection was complete as determined by LCMS. The product was purified
using preparative HPLC—MS (C18 eluting with a gradient of zO containing
0.15% NH4OH). The eluent was frozen and lyophilized to afford the product as the
free base (6.0 mg, 54%). 1H NMR (400 MHz, CD3OD) 5 8.74 (s, 1H), 8.67 (s, 1H),
8.40 (s, 1H), 7.51 (d, J= 3.6 Hz, 1H), 7.37 (s, 1H), 7.00 — 6.97 (m, 2H), 5.23 — 5.00
(m, 1H), 3.90 (d, J= 14.8 Hz, 1H), 3.81 (d, J=14.8 Hz, 1H), 3.50 (dd, J=10.9, 4.9
Hz, 1H), 3.41 (dd, J= 10.9, 6.9 Hz, 1H), 3.31 (s, 2H), 3.16 — 3.05 (m, 2H), 2.95 (p, J
= 7.5 Hz, 1H), 2.83
— 2.63 (m, 3H), 2.56 — 2.42 (m, 2H), 2.39 — 2.23 (m, 2H), 2.19 —
2.04 (m, 2H), 1.93 — 1.75 (m, 2H), 1.05 (d, J= 6.4 Hz, 3H). 19F NMR (376 MHz,
CD30D) 5 —70.30 (s). LCMS (M+H)+: 610.3
Example 22. {trans(4—{[4—({[(2R)—2-hydroxypr0pyl]amino}methyl)—6-
(trifluoromethyl)pyridinyl] peridinyl)[4—(7H—pyrrolo [2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl] cyclobutyl} acetonitrile
fig:\N F
O F
NH
The procedure of Example 9 ofUS 2014/0005166 was followed, using (2R)—1—
aminopropanol (12 uL, 0.15 mmol, Aldrich) in the cement step, which was
carried out at 50 0C for 2 hours. The product was obtained as the free base (8.7 mg,
46%). 1H NMR (400 MHz, d6-DMSO) 5 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H),
8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.42 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (s,
1H), 5.11 — 4.90 (m, 1H), 4.49 (d, J= 4.4 Hz, 1H), 3.76 (s, 2H), 3.67 (tt, J= 10.3, 5.6
Hz, 1H), 3.42 (s, 2H), 3.11 — 2.96 (m, 2H), 2.81 (p, J: 7.5 Hz, 1H), 2.74 — 2.56 (m,
2H), 2.46 — 2.25 (m, 4H), 2.24 — 2.09 (m, 2H), 2.09 — 1.90 (m, 2H), 1.81 — 1.51 (m,
2H), 1.03 (d, J: 6.2 Hz, 3H). 19F NMR (376 MHz, O) 5 -67.29 (s). LCMS
(M+H)+: 610.3.
Example 23. {trans(4—{[4-({[(2S)—2-hydr0xypropyl]amino}methyl)—6-
(trifluoromethyl)pyridinyl] oxy}piperidinyl)[4—(7H—pyrrolo [2,3-
d]pyrimidin-4—yl)—1H-pyrazol—l-yl] cyclobutyl}acetonitrile
The procedure of e 9 ofUS 2014/0005166 was followed, using (2S)—1—
aminopropanol (12 uL, 0.15 mmol, Aldrich) in the displacement step, which was
carried out at 50 0C for 2 hours (7.9 mg, 42%). 1H NMR (400 MHz, d6—DMSO) 5
12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.42
(s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (s, 1H), 5.27 — 4.71 (m, 1H), 4.49 (d, J: 4.4
Hz, 1H), 3.76 (s, 2H), 3.72 — 3.62 (m, 1H), 3.42 (s, 2H), 3.09 — 2.96 (m, 2H), 2.81 (p,
J: 7.4 Hz, 1H), 2.72 — 2.55 (m, 2H), 2.43 — 2.25 (m, 4H), 2.25 — 2.08 (m, 2H), 2.08 —
1.96 (m, 2H), 1.78 — 1.57 (m, 2H), 1.03 (d, J= 6.2 Hz, 3H). 19F NMR (376 MHz, d6—
DMSO) 5 —67.29 (s). LCMS (M+H)+: 610.3.
Example 24. {trans(4—{[4-(2-hydroxyethyl)—6-(triflu0r0methyl)pyridin
yl]oxy}piperidinyl)[4-(7H-pyrrolo [2,3-d]pyrimidin-4—yl)—1H-pyrazol—l-
yl] cyclobutyl}acetonitrile
{trans-3 -(4- { [4-(2-hydroxyethyl)(trifluoromethyl)pyridin
}piperidinyl)[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3 -
d]pyrimidinyl)—lH-pyrazol-l-yl]cyclobutyl}acetonitrile (9.0 mg, 0.013 mmol, Peak
2 from ediate Example A4 ofUS 2014/0005166, Step 3) was deprotected and
purified by stirred in a mixture of methylene chloride (0.50 mL) and trifluoroacetic
acid (0.50 mL) for one hour. The solvents were removed in vacuo and the residue was
d in methanol (0.1 mL) containing ethylenediamine (0.1 mL). Purification via
preparative HPLC-MS (C18 eluting with a gradient of MeCN/HzO containing 0.15%
NH4OH) afforded t as the free base (5.8 mg, 79%). 1H NMR (300 MHz, d6-
DMSO) 5 12.12 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz,
1H), 7.34 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.95 (s, 1H), 4.99 (tt, J: 8.2, 4.1 Hz, 1H),
4.73 (t, J= 4.9 Hz, 1H), 3.66 (q, J= 5.9 Hz, 2H), 3.42 (s, 2H), 3.11 — 2.95 (m, 2H),
2.90 — 2.71 (m, 3H), 2.71— 2.56 (m, 2H), 2.44 — 2.30 (m, 2H), 2.15 (t, J: 9.2 Hz,
2H), 2.09 — 1.82 (m, 2H), 1.83 — 1.58 (m, 2H). 19F NMR (282 MHz, d6—DMSO) 5 —
67.26 (s). LCMS (M+H)+: 567.2.
Example A: In vitro JAK Kinase Assay
Compounds herein were tested for inhibitory activity of JAK targets according
to the following in vitro assay described in Park et al., Analytical Biochemistry 1999,
269, 94-104. The tic domains of human JAKl (a.a. 837-1142), JAK2 (a.a. 828-
1132) and JAK3 (a.a. 781—1124) with an N—terminal His tag were expressed using
baculovirus in insect cells and purified. The catalytic activity of JAKl, JAK2 or JAK3
was assayed by measuring the orylation of a ylated e. The
phosphorylated peptide was detected by homogenous time resolved fluorescence
(HTRF). ICsos of compounds were ed for each kinase in the 40 microL
reactions that contain the enzyme, ATP and 500 nM peptide in 50 mM Tris (pH 7.8)
buffer with 100 mM NaCl, 5 mM DTT, and 0.1 mg/mL (0.01%) BSA. For the 1 mM
ICso measurements, ATP concentration in the reactions was 1 mM. Reactions were
carried out at room temperature for 1 hour and then stopped with 20 uL 45 mM
EDTA, 300 nM SA-APC, 6 nM Eu-Py20 in assay buffer (Perkin Elmer, Boston, MA).
Binding to the Europium d antibody took place for 40 minutes and HTRF signal
was measured on a Fusion plate reader (Perkin Elmer, Boston, MA). See Table 2 for
data for compounds of the examples as tested by the assay of e A at 1 mM
ATP.
Example B: Cellular Assays
Cancer cell lines dependent on cytokines and hence JAK/STAT signal
transduction, for , can be plated at 6000 cells per well (96 well plate format) in
RPMI 1640, 10% FBS, and l nG/mL of appropriate cytokine. Compounds can be
added to the cells in DMSO/media (final concentration 0.2% DMSO) and incubated
for 72 hours at 37 OC, 5% C02. The effect of compound on cell viability is assessed
using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) ed by
TopCount (Perkin Elmer, Boston, MA) quantitation. Potential off-target effects of
compounds are measured in parallel using a non-JAK driven cell line with the same
assay readout. All experiments are typically performed in duplicate.
The above cell lines can also be used to examine the effects of compounds on
orylation of JAK kinases or potential downstream substrates such as STAT
proteins, Akt, Shp2, or Erk. These experiments can be performed following an
overnight cytokine starvation, followed by a brief preincubation with compound (2
hours or less) and ne stimulation of approximately 1 hour or less. ns are
then extracted from cells and analyzed by techniques familiar to those schooled in the
art including Western blotting or ELISAs using antibodies that can differentiate
between phosphorylated and total protein. These experiments can e normal or
cancer cells to investigate the activity of compounds on tumor cell survival biology or
on mediators of inflammatory disease. For example, with regards to the latter,
cytokines such as IL-6, IL-12, IL-23, or IFN can be used to stimulate JAK activation
resulting in phosphorylation of STAT n(s) and potentially in transcriptional
profiles (assessed by array or qPCR technology) or tion and/or secretion of
proteins, such as IL-l7. The ability of nds to inhibit these cytokine mediated
effects can be measured using techniques common to those schooled in the art.
Compounds herein can also be tested in cellular models designed to evaluate
their potency and activity against mutant JAKs, for example, the JAK2V617F
mutation found in myeloid proliferative disorders. These experiments often utilize
ne dependent cells of hematological lineage (e.g. BaF/3) into which the wild-
type or mutant JAK kinases are ectopically expressed , C., et al. Nature
434: 1 144-1 148; Staerk, J., et a]. JBC 280:41893—41899). Endpoints include the
effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT,
Akt, or Erk proteins.
Certain compounds herein can be evaluated for their ty inhibiting T-cell
eration. Such as assay can be considered a second cytokine (lie. JAK) driven
proliferation assay and also a simplistic assay of immune suppression or inhibition of
immune activation. The following is a brief outline of how such experiments can be
performed. Peripheral blood mononuclear cells ) are prepared from human
whole blood samples using Ficoll Hypaque separation method and T-cells (fraction
2000) can be obtained from PBMCs by elutriation. Freshly isolated human s can
be maintained in culture medium (RPMI 1640 supplemented with10% fetal bovine
serum, 100 U/ml llin, 100 ug/ml streptomycin) at a density of 2 x 106 cells/ml at
37 0C for up to 2 days. For IL-2 stimulated cell eration analysis, T-cells are first
treated with Phytohemagglutinin (PHA) at a final concentration of 10 ug/mL for 72
hours. After washing once with PBS, 6000 cells/well are plated in 96-well plates and
treated with compounds at different trations in the culture medium in the
presence of 100 U/mL human IL—2 (ProSpec-Tany TechnoGene; Rehovot, Israel).
The plates are incubated at 37 0C for 72h and the proliferation index is assessed using
CellTiter—Glo Luminescent reagents following the ctory suggested protocol
(Promega; Madison, WI).
Assay C. SlOOA9 Transgenic Mouse Model
It was previously shown that S100A9 transgenic mice display bone marrow
accumulation of MDSC accompanied by development of progressive multilineage
cytopenias and cytological dysplasia similar to MDS. Further, early forced
maturation of MDSC by either all-trans-retinoic acid ent or active
immunoreceptor tyrosine-based activation bearing (ITAM-bearing) adapter
protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype
and mitigated the disease. This system can be useful to test the effects on JAKl
inhibition on MDS-like disease in a preclinical model. J. Clin. Invest, 123(1 l):4595—
4611 (2013), Accordingly, a JAKl selective inhibitor is dosed by oral gavage. The
compound’s ability to reduce the cytopenias and cytological sia observed in the
S100A9 transgenic mice is red.
All patents, patent applications, journal articles and books are incorporated
herein by reference in their entireties.
Claims (33)
1. Use of a JAK1 selective inhibitor in the manufacture of a medicament for the ent of a myelodysplastic syndrome in a patient in need f, wherein said medicament comprises a therapeutically effective amount of a JAK1 selective inhibitor selected from: 6-chloropyridinyl)pyrrolidinyl][4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-1H-pyrazolyl]propanenitrile; 3-(1-[1,3]oxazolo[5,4-b]pyridinylpyrrolidinyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]propanenitrile; 4-[(4-{3-cyano[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]propyl}piperazinyl)carbonyl]fluorobenzonitrile; 4-[(4-{3-cyano[3-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrrol yl]propyl}piperazinyl)carbonyl]fluorobenzonitrile; {1-{1-[3-Fluoro(trifluoromethyl)isonicotinoyl]piperidinyl}[4-(7H- pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}acetonitrile; 4-{3-(cyanomethyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}-N-[4-fluoro(trifluoromethyl)phenyl]piperidine carboxamide; [3-[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazolyl](1-{[2- (trifluoromethyl)pyrimidinyl]carbonyl}piperidinyl)azetidin yl]acetonitrile; [trans[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazolyl](4-{[2- (trifluoromethyl)pyrimidinyl]carbonyl}piperazin yl)cyclobutyl]acetonitrile; {trans(4-{[4-[(3-hydroxyazetidinyl)methyl](trifluoromethyl)pyridin yl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol- yclobutyl}acetonitrile; {trans(4-{[4-{[(2S)(hydroxymethyl)pyrrolidinyl]methyl} (trifluoromethyl)pyridinyl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]cyclobutyl}acetonitrile; {trans (4-{[4-{[(2R)(hydroxymethyl)pyrrolidinyl]methyl} uoromethyl)pyridinyl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]cyclobutyl}acetonitrile; 4-(4-{3-[(dimethylamino)methyl]fluorophenoxy}piperidinyl)[4-(7H- pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazolyl]butanenitrile; 5-{3-(cyanomethyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}-N-isopropylpyrazinecarboxamide; 4-{3-(cyanomethyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}-2,5-difluoro-N-[(1S)-2,2,2-trifluoro methylethyl]benzamide; 5-{3-(cyanomethyl)[4-(1H-pyrrolo[2,3-b]pyridinyl)-1H-pyrazol yl]azetidinyl}-N-isopropylpyrazinecarboxamide; {1-(cis {[6-(2-hydroxyethyl)(trifluoromethyl)pyrimidin yl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}acetonitrile; {1-(cis {[4-[(ethylamino)methyl](trifluoromethyl)pyridin yl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}acetonitrile; {1-(cis {[4-(1-hydroxymethylethyl)(trifluoromethyl)pyridin yl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol yl]azetidinyl}acetonitrile; {1-(cis {[4-{[(3R)hydroxypyrrolidinyl]methyl} (trifluoromethyl)pyridinyl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}acetonitrile; {1-(cis {[4-{[(3S)hydroxypyrrolidinyl]methyl} (trifluoromethyl)pyridinyl]oxy}cyclohexyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}acetonitrile; {trans (4-{[4-({[(1S)hydroxymethylethyl]amino}methyl) (trifluoromethyl)pyridinyl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]cyclobutyl}acetonitrile; {trans {[4-({[(2R)hydroxypropyl]amino}methyl) (trifluoromethyl)pyridinyl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]cyclobutyl}acetonitrile; {trans(4-{[4-({[(2S)hydroxypropyl]amino}methyl) (trifluoromethyl)pyridinyl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3- midinyl)-1H-pyrazolyl]cyclobutyl}acetonitrile; and {trans(4-{[4-(2-hydroxyethyl)(trifluoromethyl)pyridin yl]oxy}piperidinyl)[4-(7H-pyrrolo[2,3-d]pyrimidinyl)-1H-pyrazol- 1-yl]cyclobutyl}acetonitrile; or a pharmaceutically acceptable salt f.
2. The use of claim 1, wherein the JAK1 selective inhibitor is selective for JAK1 over JAK2, JAK3, and TYK2.
3. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is refractory cytopenia with unilineage sia (RCUD).
4. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is tory anemia with ring sideroblasts (RARS).
5. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is tory cytopenia with multilineage dysplasia.
6. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is refractory anemia with excess blasts-1 (RAEB-1).
7. The use of claim 1 or claim 2, wherein said myelodysplastic me is refractory anemia with excess blasts-2 (RAEB-2).
8. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is myelodysplastic syndrome, unclassified (MDS-U).
9. The use of claim 1 or claim 2, wherein said myelodysplastic syndrome is myelodysplastic syndrome associated with isolated del(5q).
10. The use of any one of claims 1 to 9, wherein said myelodysplastic me is refractory to erythropoiesis-stimulating agents.
11. The use of any one of claims 1 to 10, wherein said patient is red blood cell transfusion dependent.
12. The use of any one of claims 1 to 11, wherein said medicament is formulated for co-administration with an additional therapeutic agent selected from an IMiD, an anti-IL-6 agent, an NF-α agent, a hypomethylating agent, or a biologic response er (BRM).
13. The use of claim 12, n said anti–TNF-α agent is selected from infliximab and etanercept.
14. The use of claim 12, wherein said hypomethylating agent is a DNA methyltransferase inhibitor.
15. The use of claim 14, wherein said DNA methyl transferase tor is selected from 5 azacytidine and decitabine.
16. The use of claim 12, wherein said IMiD is selected from thalidomide, lenalidomide, pomalidomide, CC-11006, and CC-10015.
17. The use of any one of claims 1 to 11, wherein said medicament is formulated for inistration with an additional therapeutic agent selected from antithymocyte globulin, recombinant human granulocyte colony-stimulating factor (G CSF), granulocyte-monocyte CSF (GM-CSF), a erythropoiesis-stimulating agent (ESA), and cyclosporine.
18. Use of a JAK1 selective inhibitor in the manufacture of a medicament for the treatment of a myelodysplastic syndrome in a patient in need thereof, the medicament comprising a JAK1 ive inhibitor which is {1-{1-[3-Fluoro (trifluoromethyl)isonicotinoyl]piperidinyl}[4-(7H-pyrrolo[2,3- d]pyrimidinyl)-1H-pyrazolyl]azetidinyl}acetonitrile, or a pharmaceutically able salt thereof.
19. The use of claim 18, wherein said myelodysplastic syndrome is refractory cytopenia with unilineage dysplasia (RCUD).
20. The use of claim 18, wherein said myelodysplastic syndrome is refractory anemia with ring sideroblasts (RARS).
21. The use of claim 18, wherein said myelodysplastic syndrome is refractory cytopenia with multilineage dysplasia.
22. The use of claim 18, wherein said myelodysplastic syndrome is refractory anemia with excess blasts-1 1).
23. The use of claim 18, wherein said myelodysplastic syndrome is refractory anemia with excess blasts-2 (RAEB-2).
24. The use of claim 18, wherein said ysplastic syndrome is myelodysplastic syndrome, unclassified (MDS-U).
25. The use of claim 18, wherein said myelodysplastic me is myelodysplastic syndrome associated with ed del(5q).
26. The use of claim 18, wherein said myelodysplastic syndrome is refractory to erythropoiesis-stimulating agents.
27. The use of any one of claims 18 to 26, wherein said t is red blood cell transfusion dependent.
28. The use of any one of claims 18 to 27, wherein said medicament is formulated for co-administration with an additional therapeutic agent selected from an IMiD, an anti-IL-6 agent, an anti–TNF-α agent, a hypomethylating agent, or a biologic se modifier (BRM).
29. The use of claim 28, wherein said anti–TNF-α agent is selected from infliximab and etanercept.
30. The use of claim 28, wherein said hypomethylating agent is a DNA methyltransferase inhibitor.
31. The use of claim 30, wherein said DNA methyl transferase inhibitor is selected from 5 azacytidine and decitabine.
32. The use of claim 28, wherein said IMiD is selected from omide, lenalidomide, pomalidomide, CC-11006, and CC-10015.
33. The use of any one of claims 18 to 27, wherein said medicament is ated for co-administration with an additional therapeutic agent selected from antithymocyte globulin, inant human granulocyte colony-stimulating factor (G CSF), granulocyte-monocyte CSF (GM-CSF), a erythropoiesis-stimulating agent (ESA), and cyclosporine.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461946124P | 2014-02-28 | 2014-02-28 | |
US61/946,124 | 2014-02-28 | ||
PCT/US2015/017963 WO2015131031A1 (en) | 2014-02-28 | 2015-02-27 | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ724464A NZ724464A (en) | 2021-01-29 |
NZ724464B2 true NZ724464B2 (en) | 2021-04-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015222913B2 (en) | JAK1 inhibitors for the treatment of myelodysplastic syndromes | |
KR102558066B1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
US9801889B2 (en) | Bicyclic heterocycles as FGFR4 inhibitors | |
JP7012534B2 (en) | Optimized combination therapies and their use to treat cancer and autoimmune diseases | |
DK2545045T3 (en) | PIPERIDINE-4-YL-azetidine derivatives AS JAK1 INHIBITORS | |
JP5881718B2 (en) | CXCR4 receptor antagonist | |
AU2019257450A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors | |
CA3157361A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
CA2839767A1 (en) | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors | |
WO2019191684A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
JP7399968B2 (en) | Pyrazolo[4,3-D]pyrimidine compounds as ALK2 and/or FGFR modulators | |
AU2017324281A1 (en) | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof | |
JP2018507236A (en) | Triazolopyridine compounds and methods of use thereof | |
JP2023503322A (en) | Novel compounds for treating diseases associated with DUX4 expression | |
NZ724464B2 (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
BR112016019511B1 (en) | USE OF JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | |
WO2024020534A2 (en) | Cyclic compounds and methods of using same | |
EA040337B1 (en) | JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | |
AU2019257385A1 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
NZ618982B2 (en) | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |